var title_f25_39_26224="Hands in acromegaly";
var content_f25_39_26224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hands in acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the hands in a patient with acromegaly, which resulted in an increase in glove size and the need to remove rings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26224=[""].join("\n");
var outline_f25_39_26224=null;
var title_f25_39_26225="Scabies burrow 3";
var content_f25_39_26225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and multiple small burrows with overlying scale are present in the interdigital space in this patient with AIDS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26225=[""].join("\n");
var outline_f25_39_26225=null;
var title_f25_39_26226="Auricular inflammation RPC";
var content_f25_39_26226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auricular inflammation in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute auricular inflammation in a patient with relapsing polychondritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26226=[""].join("\n");
var outline_f25_39_26226=null;
var title_f25_39_26227="Clindamycin and tretinoin: Pediatric drug information";
var content_f25_39_26227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin and tretinoin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13155?source=see_link\">",
"    see \"Clindamycin and tretinoin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/52/23364?source=see_link\">",
"    see \"Clindamycin and tretinoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4001006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Veltin&trade;;",
"     </li>",
"     <li>",
"      Ziana&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13826445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Retinoic Acid Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13826453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13155?source=see_link\">",
"      see \"Clindamycin and tretinoin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Children &ge;12 years and Adults: Topical: Apply pea-size amount to entire face once daily at bedtime;",
"     <b>",
"      Note:",
"     </b>",
"     Higher dosages (larger amount or more frequent use) have not been shown to improve efficacy and are associated with increased adverse effects (eg, skin irritation)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4001037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Veltin&trade;: Clindamycin phosphate 1.2% and tretinoin 0.025% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ziana&reg;: Clindamycin phosphate 1.2% and tretinoin 0.025% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4001008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13826454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to application, clean face with a mild soap and pat dry; place pea-size amount on one fingertip and then dot on chin, cheeks, nose, and forehead. Gently rub over entire face or entire affected area while avoiding eyes, lips, mouth, angles of nose, and mucous membranes. Wash hands after use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13826450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from heat and light; when not in use, tube should be kept tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13826446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4001023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Burning, dermatitis, dryness, erythema, exfoliation, irritation, pruritus, scaling, stinging, sunburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: GI symptoms (unspecified)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasopharyngitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13826447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clindamycin, tretinoin, or any component; regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13826458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution or discontinue therapy in patients undergoing elective surgery. Use with caution in patients receiving erythromycin-containing products; may decrease effect of clindamycin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13826448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clindamycin systemic absorption has been observed with topical use; prolonged use of clindamycin may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; characterized by severe persistent diarrhea, severe abdominal cramps, and possibly, the passage of blood and mucus; CDAD has been observed &gt;2 months postantibiotic treatment; discontinue drug if significant diarrhea occurs. Antiperistaltic agents, such as opiates or diphenoxylate with atropine, may prolong and worsen the condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tretinoin use is associated with increased susceptibility/sensitivity to UV light; avoid sunlamps or excessive sunlight exposure. Daily sunscreen use and other protective measures are recommended. Tretinoin therapy can increase skin sensitivity to weather extremes of wind or cold. Also, concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be used with caution due to increased skin irritation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For   external use only; avoid mucous membranes, eyes, mouth, and angles of nose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ziana&trade;  topical gel contains polysorbate 80 (Tween 80) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4001025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4001014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4001015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in topical animal studies. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13826594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for changes in bowel frequency.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13826451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clindamycin reversibly binds to 50S ribosomal subunits, preventing peptide chain elongation, thus inhibiting bacterial protein synthesis. Clindamycin exhibits",
"     <i>",
"      in vitro",
"     </i>",
"     activity against",
"     <i>",
"      Propionibacterium acnes",
"     </i>",
"     , an organism associated with acne vulgaris. Topical tretinoin is believed to decrease follicular epithelial cells cohesiveness and increase follicular epithelial cell turnover, resulting in decreased microcomedo formation and increased expulsion of comedones.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13826452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Tretinoin: Minimal systemic absorption; Clindamycin: Low and variable systemic absorption",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13826455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/52/23364?source=see_link\">",
"      see \"Clindamycin and tretinoin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands thoroughly before applying. Apply as directed; more frequent use does not improve efficacy and worsens skin irritation. Avoid eyes, lips, mouth, angles of nose, and mucous membranes during application. Wash hands after use. When not in use, tube should be kept tightly closed. Report persistent burning, swelling, itching, excessive dryness, worsening of condition, photosensitivity reactions, or diarrhea (do not take antidiarrheal agents without consulting prescriber). May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]. Avoid washing face more frequently than 2-3 times/day; avoid using topical preparations with high alcoholic content, abrasive soaps/cleansers, or erythromycin during treatment period.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83323 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26227=[""].join("\n");
var outline_f25_39_26227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001006\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826445\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826453\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001037\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001008\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826454\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826450\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001023\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826458\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826448\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299060\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001025\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001014\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4001015\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826594\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826451\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826452\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826455\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13155?source=related_link\">",
"      Clindamycin and tretinoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/52/23364?source=related_link\">",
"      Clindamycin and tretinoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26228="Extended right colectomy";
var content_f25_39_26228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extended right colectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depcits the boundaries of an extended right hemicolectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26228=[""].join("\n");
var outline_f25_39_26228=null;
var title_f25_39_26229="The life cycle, natural history, and immunology of human papillomaviruses";
var content_f25_39_26229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The life cycle, natural history, and immunology of human papillomaviruses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Philip E Castle, PhD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26229/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/39/26229/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomaviruses (HPV) are highly prevalent, species- and tissue-specific DNA viruses that infect epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Persistent viral infection with carcinogenic HPV genotypes causes virtually all cancer of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Carcinogenic HPV infections also cause most cancers of the anus, vagina, vulva, penis, and about a third to a half of the cancers of the oropharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical cancer is the third most common cancer in women worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Although Pap",
"    <span class=\"nowrap\">",
"     testing/cytologic",
"    </span>",
"    screening has reduced the incidence of cervical cancer by 70 percent or more where it has been effectively implemented, cervical cancer remains a leading cause of death in countries without effective screening programs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the etiologic link between persistent carcinogenic HPV infection of the cervix and cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/3,4,11\">",
"     3,4,11",
"    </a>",
"    ] and its immediate precursor lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/12\">",
"     12",
"    </a>",
"    ], one approach for the prevention of cervical disease is HPV vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/13\">",
"     13",
"    </a>",
"    ]. This topic will review the life cycle, natural history and immune response to HPV and clinical trial data on the efficacy and safety data related to the available formulations of HPV vaccines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HPV GENOTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 40 mucosal HPV genotypes infect the lower female genital tract. Approximately 15 HPV types can cause all cervical cancer worldwide and are known as carcinogenic, high-risk, or cancer-associated HPV types [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/5\">",
"     5",
"    </a>",
"    ]. The carcinogenic genotypes of HPV16 and HPV18, which are targeted by the current versions of the HPV vaccine, cause approximately 70 percent of all cervical cancers worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Productive viral infections lead to cervical abnormalities that are classified according to specimen (eg, cytology or histology) and by severity (eg, mild, moderate, or severe). Mild and morphologic changes that are the result of production HPV infections are classified as cytologic low-grade squamous intraepithelial lesion [LSIL] or histologic cervical intraepithelial neoplasia grade 1 [CIN1], whereas cervical precancerous lesions are classified as cytologic high-grade squamous intraepithelial lesion [HSIL] or histologic CIN2 or CIN3",
"    <span class=\"nowrap\">",
"     [CIN2/3].",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV6 and HPV11 cause approximately 90 percent of genital warts or condyloma acuminatum.",
"   </p>",
"   <p>",
"    It is estimated that targeted HPV protection with the bivalent or quadrivalent vaccine would prevent approximately half of high-grade precancerous lesions (CIN2 or 3) and 70 percent of invasive cancers; the quadrivalent vaccine would also prevent most genital warts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HPV LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPVs are small, non-enveloped, capsid viruses, with an eight kilobase circular genome that encodes eight genes including two encapsulating structural proteins, L1 and L2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/16\">",
"     16",
"    </a>",
"    ]. The L1 protein, expressed recombinantly in a cell-culture system, self-assembles in the absence of the viral genome to form a virus-like particle (VLP). The L1 VLP is the immunogen used in the HPV vaccines. L2 is the minor capsid protein that along with L1 mediates HPV infectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The life cycle of the virus is integrally linked to epithelial differentiation, (ie, the maturation of the keratinocyte). Initial infection of the basal stem cell occurs as the result of microscopic breaks in the epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. The infecting HPV virions appear to attach to the basal stem cell via tissue-specific heparan sulfate proteoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific gene products are transcribed at every level of differentiation of the squamous keratinocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/1\">",
"     1",
"    </a>",
"    ]. At the most superficial level, the genes for the L1, L2, and E4 genes are transcribed for assembly of the viral capsid into which the HPV genome is packaged. Upon desquamation of this short-lived cell, infectious HPV virions are released for the next round of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HPV NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new paradigm of cervical carcinogenesis replaces an older pathology model of stepwise progression from low-grade to high-grade morphological changes and can now be summarized as four reliably measured stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HPV acquisition",
"     </li>",
"     <li>",
"      HPV persistence (versus viral clearance)",
"     </li>",
"     <li>",
"      Progression of a persisting infection to a precancerous lesion",
"     </li>",
"     <li>",
"      Local invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Globally, HPV is the most common sexually transmitted infection. Like all sexually transmitted infections, peak prevalence of HPV infection typically occurs within the first decade after sexual debut, typically between the ages of 15 to 25 years in most western countries. A secondary, minor peak of HPV prevalence has been observed in some populations after menopause, although neither its cause (eg, new infection or reactivation) nor its clinical importance (eg, malignancy risk) is understood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. In China, the prevalence of HPV remains uniformly high at all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/23\">",
"     23",
"    </a>",
"    ]. The cause of this is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that at least 50 percent of sexually active women (and men) are exposed to HPV once in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/24\">",
"     24",
"    </a>",
"    ]. However, many experts believe that virtually all sexually active adults have been infected by HPV for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most HPV infections are transient, and can come and go between measures of HPV [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/2,25\">",
"       2,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      There are more than 40 HPV types that infect the entire lower genital tract, including the vagina [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/18,19,26,27\">",
"       18,19,26,27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most HPV infections, including carcinogenic HPV genotypes, typically resolve within 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. However, women with persistent carcinogenic HPV infections are at risk of developing precancerous lesions, although not all persistent infections progress. In the United States, the median age of cytologically-detected precancerous lesions occurs approximately 10 years after the median age of sexual debut [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNE RESPONSE TO HPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough knowledge of what is known and unknown about the interaction between the immune system and HPV is important in understanding the potential contribution of immunization in reducing the incidence of cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best evidence to date of the general importance of the immune response in the natural history of HPV is from data linkage studies of cancer incidence in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    populations and solid organ transplant populations. A recent meta-analysis has shown that there is an elevated risk of HPV-attributable cancers in both of these patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of HPV-associated cancers in HIV-infected patients appears to be inversely related to CD4+ counts and higher levels of HIV RNA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV infection evades the immune system through a variety of mechanisms, although the molecular details remain elusive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/5\">",
"     5",
"    </a>",
"    ]. Although most women clear the infection within a few months, those who do not are at risk for development of cervical precancer and cancer. The virus may induce a shift towards immune tolerance that can facilitate persistence. Some of the proposed mechanisms used by HPV to avoid immune surveillance include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infecting only cells of the basal layer of the cervical epithelium",
"     </li>",
"     <li>",
"      Limiting expression of viral proteins until later stages of epithelial differentiation,",
"     </li>",
"     <li>",
"      Virally-mediated suppression of the proinflammatory proteins that activate cytotoxic T lymphocytes, which assist in killing infected cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women who are found to have prevalent HPV infection and CIN, there appears to be a reduction in the number and change in the phenotypic distribution of antigen-presenting cells (Langerhans' cells). Poor helper (CD4) and cytotoxic (CD8) T lymphocyte responses against HPV antigens seem to be associated with HPV infection and cervical disease. Yet, efforts to identify specific subsets of T cells responsible for clearance remain inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiological studies in diverse populations have shown the human leukocyte antigen DRB1*1301 is associated with a decrease risk of precancer and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition to acquired immune responses, innate immunity could also have an important role at the mucosal level [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26229/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent viral infection with carcinogenic HPV genotypes causes virtually all cancer of the cervix. Carcinogenic HPV infections also cause most cancers of the anus, vagina, vulva, penis, and about a third to a half of the cancers the oropharynx. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The carcinogenic genotypes of HPV16 and HPV18, which are targeted by the current versions of the HPV vaccine, cause approximately 70 percent of all cervical cancers worldwide. HPV6 and HPV11 cause approximately 90 percent of genital warts or condyloma acuminatum. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'HPV genotypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The L1 protein self-assembles in the absence of the viral genome to form a virus-like particle (VLP), which is the immunogen used in HPV vaccines. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HPV life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most HPV infections, including carcinogenic HPV genotypes, typically resolve within 6 to 12 months. However, women with persistent carcinogenic HPV infections are at risk of developing precancerous lesions, although not all persistent infections progress. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HPV natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The importance of the immune response in the natural history of HPV is illustrated by the increased risk of cancer among immunosuppressed or immunocompromised patient populations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immune response to HPV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/1\">",
"      Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/2\">",
"      de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/3\">",
"      Mu&ntilde;oz N, Bosch FX, de Sanjos&eacute; S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/4\">",
"      Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/5\">",
"      Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/6\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/7\">",
"      D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/8\">",
"      Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467.",
"     </a>",
"    </li>",
"    <li>",
"     Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. file://globocan.iarc.fr (Accessed on April 27, 2012).",
"    </li>",
"    <li>",
"     Cervix Cancer Screening. IARC Press, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/11\">",
"      Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/12\">",
"      Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/13\">",
"      Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005; 353:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/14\">",
"      de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/15\">",
"      Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/16\">",
"      Yang R, Yutzy WH 4th, Viscidi RP, Roden RB. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 2003; 278:12546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/17\">",
"      Yang R, Day PM, Yutzy WH 4th, et al. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 2003; 77:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/18\">",
"      Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/19\">",
"      Johnson KM, Kines RC, Roberts JN, et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2009; 83:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/20\">",
"      Selinka HC, Florin L, Patel HD, et al. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 2007; 81:10970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/21\">",
"      Shafti-Keramat S, Handisurya A, Kriehuber E, et al. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003; 77:13125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/22\">",
"      Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/23\">",
"      Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131:2929.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/HPV/STDFact-HPV.htm (Accessed on April 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/25\">",
"      Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/26\">",
"      Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003; :35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/27\">",
"      Carrington M, Wang S, Martin MP, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005; 201:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/28\">",
"      Rodr&iacute;guez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/29\">",
"      Castle PE, Fetterman B, Akhtar I, et al. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 2009; 114:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/30\">",
"      Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/31\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26229/abstract/32\">",
"      Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 Suppl 1:S16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8326 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26229=[""].join("\n");
var outline_f25_39_26229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HPV GENOTYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HPV LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HPV NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNE RESPONSE TO HPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26230="Headache in ER I";
var content_f25_39_26230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71604%7EEM%2F51917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71604%7EEM%2F51917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Management of headache in the emergency department-I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 479px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Management of headache in the emergency department-II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 650px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; CSF: cerebrospinal fluid; CT: computed tomography scan; LP: lumbar puncture; RBC: red blood cell; WBC: white blood cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26230=[""].join("\n");
var outline_f25_39_26230=null;
var title_f25_39_26231="Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer";
var content_f25_39_26231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Thomas J Herzog, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26231/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/39/26231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three tumor origins under the heading EOC.",
"   </p>",
"   <p>",
"    EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Only approximately 25 percent of women will be diagnosed with early stage ovarian cancer, either confined to the ovary (stage I) or confined to the pelvis (stage II). For women with EOC confined to the ovary (IA or IB)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    well-differentiated (grade 1) tumors, prognosis is excellent with survival of at least 90 percent following surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For all others, adjuvant chemotherapy is recommended.",
"   </p>",
"   <p>",
"    This section will review adjuvant therapy for early stage EOC. Initial surgical management, adjuvant therapy for women with advanced (stage III or IV) ovarian cancer, and chemotherapy for women with recurrent disease are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"       Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       Epithelial ovarian cancer: Initial surgical management",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21075699\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of women with early-stage disease at increased risk of relapse and can be identified based on the presence of high-risk features including: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IC (tumor confined to the ovary with positive peritoneal washings) or stage II (tumor involving the pelvis) disease",
"     </li>",
"     <li>",
"      Clear cell histology (any stage)",
"     </li>",
"     <li>",
"      High tumor grade (grade 3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These high risk features are used as criteria to determine eligibility for adjuvant therapy in clinical trials of women with early-stage disease and for the use of adjuvant therapy outside of clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/3\">",
"     3",
"    </a>",
"    ]. For women with these features, five-year disease-free survival rates range from 40 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. This compares to a five year survival rate of at least 90 percent among women with well-differentiated (grade 1) tumors confined to the ovary (stage IA or IB) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is controversial whether women with grade 2 ovarian cancer should be considered as having high risk disease and offered adjuvant therapy.",
"   </p>",
"   <p>",
"    The benefit of adjuvant chemotherapy in patients with early stage EOC has been further shown in two meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, 13 trials conducted between 1965 and 2004 were included, although only eight of these studies were performed exclusively in stage I ovarian cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The pooled results for chemotherapy for women with stage I ovarian cancer showed a benefit for adjuvant treatment in terms of recurrence-free survival (Relative Risk [RR] 0.70, 95% CI 0.58-0.86) and overall survival (RR 0.74, 95% CI 0.58-0.94).",
"     </li>",
"     <li>",
"      Five-year overall survival was improved with the use of adjuvant platinum-based therapy (HR 0.67, 95% CI 0.50-0.90).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the second, five randomized trials conducted between 1990 and 2003 involving 1277 women were included in the analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/7\">",
"       7",
"      </a>",
"      ]. Again, adjuvant chemotherapy was associated with benefit in terms of both progression-free survival (HR 0.67, 95% CI 0.52-0.84) and overall survival (HR 0.71, 95% CI 0.53-0.93).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women who had no gross residual following surgery, chemotherapy did not appear to improve overall survival when compared with observation (HR 1.22, 95% CI 0.63-2.37). In comparison, for women who had incompletely resected disease, chemotherapy resulted in superior survival when compared with observation (HR 0.63, 95% CI 0.46-0.85).",
"     </li>",
"     <li>",
"      Women with high-risk tumors had a survival advantage with the use of adjuvant chemotherapy over observation (HR 0.48, 95% CI 0.32-0.72). Those with low-risk tumors did not derive a benefit from chemotherapy (HR 0.95, 95% CI 0.54-1.66).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent publication of the Adjuvant Chemotherapy in Ovarian Neoplasms (ACTION) trial has questioned the benefit of adjuvant chemotherapy in early stage disease following complete surgical staging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/8\">",
"     8",
"    </a>",
"    ]. The ACTION study enrolled 448 women with early EOC and high risk features and randomly assigned post surgical care to adjuvant platinum-based chemotherapy versus observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/9\">",
"     9",
"    </a>",
"    ]. While surgical treatment was not protocol mandated, the study incorporated strict definitions of optimal versus non-optimal staging. After a median follow-up of ten years, adjuvant chemotherapy resulted in the following outcomes when compared with observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in recurrence free survival (RFS, 70 versus 62 percent, HR 0.64, 95% CI 0.46-0.89) and a trend towards an improvement in cancer specific survival (CSS, 82 versus 76 percent, HR 0.73, 95% CI 0.48-1.13).",
"     </li>",
"     <li>",
"      For women who underwent complete surgical staging, there was no significant improvement in either RFS (78 versus 72 percent, HR 0.73, 95% CI 0.38-1.42) or CSS (85 versus 89 percent, HR 1.58, 95% CI 0.61-4.08). However, for women who had incomplete surgical staging, there was a significant improvement in both RFS (65 versus 56 percent, HR 0.60, 95% CI 0.41-0.87) and CSS (80 versus 69 percent, HR 0.58, 95% CI 0.35-0.95).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the available evidence supports the use of adjuvant chemotherapy in patients with early stage ovarian cancer with high risk features. In contrast, patients with no risk factors do not appear to benefit from chemotherapy. Further prospective clinical trials are needed to determine whether patients with one or more of these high risk features who have undergone optimal surgical staging may omit adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    Our approach is consistent with that of the National Comprehensive Cancer Network guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/10\">",
"     10",
"    </a>",
"    ]. For women with resected grade 1, stage IA or IB disease, we recommend observation alone rather than the use of adjuvant therapy. For women with high-risk disease (defined as stage IC or II, high grade or clear cell cancers of any stage), we recommend adjuvant chemotherapy. We also suggest the use of adjuvant chemotherapy for women with grade 2 tumors but acknowledge that observation, in the absence of other risk factors, is an acceptable alternative for this subgroup of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF ADJUVANT TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1173577\">",
"    <span class=\"h2\">",
"     Intravenous chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, adjuvant therapy is offered to women with early-stage EOC with high-risk features. For such women, adjuvant intravenous chemotherapy is the preferred modality. While the optimal adjuvant chemotherapy regimen is unknown, most clinicians offer treatment with a platinum-based doublet, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , largely because of its demonstrated efficacy in the adjuvant therapy of women with advanced stage EOC (",
"    <a class=\"graphic graphic_table graphicRef65626 \" href=\"UTD.htm?6/57/7070\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both intravenous platinum-based chemotherapy and intraperitoneal P 32 have been evaluated as the adjuvant treatment in this population. Several trials have compared platinum-based chemotherapy (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alone or cisplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) with P 32 in women with early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. In each of these, P 32 therapy was associated with increased toxicity without improved efficacy. In particular, P 32 therapy was complicated by problems with adequate distribution and bowel toxicity (eg, perforation). Given the effectiveness of chemotherapy, intraperitoneal P 32 has been abandoned and is no longer used in the treatment of early stage ovarian cancer.",
"   </p>",
"   <p>",
"    There is a lack of consensus regarding the optimal adjuvant regimen in this setting. We prefer a platinum-based doublet (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) largely based upon indirect evidence that it improves outcomes when administered as adjuvant therapy for more advanced disease (",
"    <a class=\"graphic graphic_table graphicRef65626 \" href=\"UTD.htm?6/57/7070\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, given the low quality data available to inform an optimal regimen, single agent carboplatin may be an acceptable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Well-designed trials are needed to identify the optimal chemotherapy regimen in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of adjuvant chemotherapy for early stage EOC is undefined. We administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for six cycles. We recognize that the benefit of six cycles may be limited to women with serous cancers or women with stage II disease. It is reasonable to individualize the number of cycles based upon patient risk factors and the tolerance of therapy, with a planed minimum of three cycles.",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the ideal number of treatment cycles in this setting. In Gynecologic Oncology Group Trial 157 (GOG 157), 457 women were treated with either three or six course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (area under the curve [AUC] 7.5) given every three weeks to 457 women with high-risk early-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared to three cycles, the administration of six cycles was associated with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonsignificant trend towards lower risk of recurrence (20 versus 25 percent)",
"     </li>",
"     <li>",
"      Similar five-year survival rate (83 versus 81 percent)",
"     </li>",
"     <li>",
"      More toxicity (neurotoxicity, granulocytopenia, and anemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent ad hoc analysis of the same trial, a significantly lower risk of recurrence was seen for six rather than three cycles of chemotherapy in patients with serous tumors (HR 0.33, 95% CI 0.14-0.77) but not other histologic types [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/17\">",
"     17",
"    </a>",
"    ]. Comparing six versus three cycles, five year overall survival was not significantly different among women with serous cancers (86 versus 73 percent). For women with other tumor types there was no difference in overall survival with three or six cycles (79 percent in both groups).",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14637718\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112932639\">",
"    <span class=\"h2\">",
"     Unstaged patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of early-stage epithelial ovarian cancer (EOC) is occasionally made during surgery for an emergent (eg, torsion) or benign (ie, ovarian cystectomy) indication. In these cases, women will not have undergone surgical staging and technically speaking would be considered to have apparent early but unstaged ovarian cancer. For women with unstaged apparent early EOC, we suggest staging because both prognosis and adjuvant treatment options are tied to disease stage. Often this surgery can be performed through a minimally invasive approach. Alternatively, some evidence suggests that surgery may not be required if adjuvant chemotherapy is administered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As described above, the Adjuvant Chemotherapy in Ovarian Neoplasm (ACTION) trial of adjuvant chemotherapy versus observation highlighted the importance of complete surgical staging in patients with early stage EOC [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/9\">",
"       9",
"      </a>",
"      ]. In this trial, the benefit of adjuvant chemotherapy was limited to patients with incomplete staging:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the 297 women who were not completely staged, adjuvant chemotherapy was associated with significant improvement in recurrence-free survival (Hazard Ratio [HR] 1.78, 95% CI 1.15-2.77) and overall survival (HR 1.75, 95% CI 1.04-2.95) compared to observation.",
"     </li>",
"     <li>",
"      For the 224 women enrolled in to the observation arm, complete staging was associated with a significant improvement in recurrence-free (HR 1.82, 95% CI 1.02-3.24) and overall survival (HR 2.31, 95% CI 1.08-4.96) over incomplete staging.",
"     </li>",
"     <li>",
"      For the 151 women who were completely staged, chemotherapy was not associated with a recurrence-free or overall survival advantage over observation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 88 patients with early stage ovarian cancer (36 unstaged), all of whom received adjuvant chemotherapy, there was no difference in outcomes among women who underwent staging after a diagnosis of EOC and those who did not undergo a second surgery for staging [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/18\">",
"       18",
"      </a>",
"      ]. The estimated rates of five-year progression free survival were 85 and 90 percent, respectively, with corresponding rates of overall survival of 85 and 88 percent.",
"     </li>",
"     <li>",
"      In a separate series of 138 patients with tumor confined to the ovary, 53 underwent adjuvant chemotherapy (34 after staging, 19 without staging performed) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/19\">",
"       19",
"      </a>",
"      ]. The relapse rate at a median follow-up of 58 months was 32 percent among staged patients and 42 percent among unstaged patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these underpowered studies suggest that it might be safe to omit formal surgical staging after a woman has been diagnosed with apparent EOC, prospective studies are needed to confirm this finding before incorporating this into standard practice. For women who choose not to undergo formal surgical staging, we recommend adjuvant chemotherapy. With grade 3 or clear cell tumors, where chemotherapy will be administered regardless of staging outcome, there may be less impetus for a secondary procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1173790\">",
"    <span class=\"h2\">",
"     Intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of adjuvant intraperitoneal (IP) chemotherapy for patients with early stage disease is experimental and is being evaluated in clinical trials. Interest in its use is based upon studies of IP chemotherapy in optimally resected advanced stage EOC that demonstrated improvements in both progression free and overall survival, but at the risk of catheter-related complications and serious gastrointestinal toxicity. The use of IP for advanced stage disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1173719\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy refers to the prolonged administration of agents with low toxicity profiles in patients who have a complete clinical response in an attempt to prevent progression of disease. Studies have investigated the use of maintenance therapy for early stage EOC. As an example, the benefit of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    versus observation was evaluated in a trial in which 571 patients were treated with three courses of paclitaxel (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (AUC 6) followed by either 24 weeks of paclitaxel (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/20\">",
"     20",
"    </a>",
"    ]. When compared with observation, maintenance paclitaxel was not associated with improvements in the five-year risk of recurrence (HR 0.807, 95% CI 0.565-1.15) or estimated rate of survival at five years (85 versus 86 percent, respectively). Grade 2 or greater adverse events were significantly increased with maintenance paclitaxel compared to observation. Given these findings, we suggest observation following adjuvant chemotherapy rather than the use of maintenance therapy for early stage EOC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H1171802#H1171802\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Maintenance chemotherapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21075706\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively uncommon detection of early stage epithelial ovarian cancer (EOC), there are few reports on survival outcomes. However, in a report from the Gynecologic Oncology Group (GOG) that assessed 506 women treated in two trials of adjuvant therapy for early stage EOC, recurrence-free and overall survival at five years were 76 and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/5\">",
"     5",
"    </a>",
"    ]. Independent predictors of inferior survival included older age, stage II disease, high tumor grade, and positive peritoneal washings. In a separate analysis of outcomes for women with early stage EOC treated on GOG 157, the recurrence rate was 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance, including the role of CA-125 measurements, for women who have completed treatment for ovarian cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099443#H6099443\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174022\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence can be detected either serologically using tumor markers (eg, CA-125)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by the development of clinical or radiologic signs of progression. We recommend re-treatment based on signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of relapsed ovarian cancer and not treating a rising CA-125 alone. This is discussed in more detail separately. In addition, indications and surgical management of recurrent disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of relapsed disease is stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PFI of six months or longer are considered to have &ldquo;platinum sensitive&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a PFI of less than six months are considered to have &ldquo;platinum-resistant&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior and are referred to as epithelial ovarian cancer (EOC). EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Approximately 25 percent of cases are early stage ovarian cancer, either confined to the ovary (stage I) or confined to the pelvis (stage II).",
"     </li>",
"     <li>",
"      Not all patients with early stage EOC require adjuvant chemotherapy. A decision to administer chemotherapy is largely based upon the stage of disease and tumor characteristics (see",
"      <a class=\"local\" href=\"#H21075699\">",
"       'Selection of patients'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with completely resected grade 1, stage IA or IB EOC, we recommend observation alone (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with high-risk EOC (defined as stage IC or II, high grade or clear cell cancers of any stage), we recommend adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We also suggest adjuvant chemotherapy for grade 2 stage I or II EOC (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Observation is an acceptable alternative for stage I EOC provided there are no high risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When adjuvant chemotherapy is used, we suggest a platinum-based two-drug combination chemotherapy regimen rather than single agent therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      for six cycles. We recognize that the benefit of six cycles may be limited to women with serous cancers or women with stage II disease. It is reasonable to individualize the number of cycles based upon patient risk factors and the tolerance of therapy. In this case, we prefer a minimum of three cycles be administered. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following adjuvant chemotherapy, we suggest observation rather than maintenance chemotherapy given the lack of an overall survival benefit associated with maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1173719\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination intraperitoneal and intravenous chemotherapy is experimental for women with early stage ovarian cancer and should be reserved for clinical trials. (See",
"      <a class=\"local\" href=\"#H1173790\">",
"       'Intraperitoneal chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The finding of early-stage EOC is occasionally made during surgery for an emergent (eg, torsion) or a benign (ie, ovarian cystectomy) indication. For these women with unstaged apparent early EOC, we suggest surgical staging because both prognosis and adjuvant treatment options are intimately tied to disease stage (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Any patient who elects not to undergo staging should receive adjuvant chemotherapy. (See",
"      <a class=\"local\" href=\"#H112932639\">",
"       'Unstaged patients'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We agree with the posttreatment surveillance recommendations from expert panels, such as the National Comprehensive Cancer Network. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099443#H6099443\">",
"       \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/1\">",
"      Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/2\">",
"      Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/3\">",
"      Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/4\">",
"      Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/5\">",
"      Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/6\">",
"      Elit L, Chambers A, Fyles A, et al. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 2004; 101:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/7\">",
"      Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2012; 3:CD004706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/8\">",
"      Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/9\">",
"      Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95:113.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed on November 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/11\">",
"      Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/12\">",
"      Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol 2003; 21:4350.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/14\">",
"      Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG 2010; 117:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/15\">",
"      du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8:viii7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/16\">",
"      Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/17\">",
"      Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/18\">",
"      Dizon DS, Restivo A, Lomme M, et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol 2008; 31:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/19\">",
"      Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002; 85:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26231/abstract/20\">",
"      Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel &times; 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2011; 122:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3199 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26231=[""].join("\n");
var outline_f25_39_26231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21075699\">",
"      SELECTION OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF ADJUVANT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1173577\">",
"      Intravenous chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14637718\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112932639\">",
"      Unstaged patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1173790\">",
"      Intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1173719\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21075706\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1174022\">",
"      TREATMENT OF RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/57/7070\" title=\"table 1\">",
"      Paclitaxel and carboplatin chemotherapy for EOC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26232="Hypersensitivity reactions to clopidogrel";
var content_f25_39_26232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypersensitivity reactions to clopidogrel",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26232/contributors\">",
"     John R Cohn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26232/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26232/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26232/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/39/26232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H264013215\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is a thienopyridine drug that inhibits platelet aggregation by blocking the adenosine diphosphate P2Y12 receptor. The most common hypersensitivity reactions to clopidogrel are dermatologic eruptions, although severe systemic reactions can also occur. The incidence and clinical manifestations of clopidogrel reactions are discussed here. Management options for the most common form of hypersensitivity reaction, dermatologic eruptions, are also reviewed. Therapeutic use of clopidogrel in the management of atherosclerotic arterial disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H547672752#H547672752\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17286097\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    are reported in up to 6 percent of patients who receive the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17286109\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of hypersensitivity reactions have been described in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258825\">",
"    <span class=\"h2\">",
"     Most common signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    hypersensitivity most commonly presents as an erythematous, macular, morbilliform rash, beginning on the face, chest, or abdomen (",
"    <a class=\"graphic graphic_picture graphicRef83637 \" href=\"UTD.htm?31/23/32118\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. It may or may not be pruritic. The rash usually spreads and becomes confluent, sometimes involving the proximal and then distal extremities. In one series, one-third of patients eventually had involvement of the entire body, including palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median time from drug introduction to appearance of symptoms is between 5 and 10 days, with a peak incidence of onset at 6 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest available series, some patients had mild elevations in leukocytes and neutrophils, platelet counts, and decreases in lymphocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact nature of the reaction is unclear, with biopsy data suggesting it is most commonly a lymphocyte-mediated reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684933\">",
"    <span class=\"h2\">",
"     Other cutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cutaneous reactions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized areas of",
"      <span class=\"nowrap\">",
"       rash/dermatitis,",
"      </span>",
"      either unilaterally or bilaterally with a symmetric distribution, usually involving the face, neck, trunk, axillae, palms, or soles [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/6\">",
"       6",
"      </a>",
"      ], isolated angioedema [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/7\">",
"       7",
"      </a>",
"      ], or both",
"     </li>",
"     <li>",
"      Pruritus without rash [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4,8\">",
"       4,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute generalized exanthematous pustulosis (AGEP) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/9\">",
"       9",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=see_link\">",
"       \"Acute generalized exanthematous pustulosis (AGEP)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall severity of cutaneous reactions is variable. In a large multicenter comparison of over 19,000 patients receiving ASA and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , cutaneous symptoms were considered severe enough to result in drug discontinuation in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258802\">",
"    <span class=\"h2\">",
"     More serious types of systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other more serious types of reactions have been described in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Although these are not discussed further in this review, clinicians should be aware that the following have been associated with clopidogrel therapy in small numbers of cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis, which is a rapidly progressing, multisystem reaction characterized by flushing, urticaria, angioedema, bronchospasm, laryngeal edema,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension (",
"      <a class=\"graphic graphic_table graphicRef58836 \" href=\"UTD.htm?22/52/23371\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome, which begins with a prodrome of malaise and fever, followed by the development of mucosal blistering and erythematous or purpuric macules and plaques on the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic",
"      </span>",
"      uremic syndrome",
"      <span class=\"nowrap\">",
"       (TTP/HUS),",
"      </span>",
"      which involves thrombocytopenia, hemolytic anemia, acute renal insufficiency, fever, and fluctuating neurologic abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic hypersensitivity syndromes consisting of rash accompanied by fever, thrombocytopenia, and neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/1,13,14\">",
"       1,13,14",
"      </a>",
"      ]. The liver and lungs may also be involved and eosinophilia is variably seen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H31#H31\">",
"       \"Drug allergy: Classification and clinical features\", section on 'Drug-induced hypersensitivity syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aplastic anemia, which presents with fatigue and increasing anemia with a reduced absolute number of reticulocytes. This is accompanied by neutropenia and thrombocytopenia. Bacterial infections may be a presenting feature [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H16#H16\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe and persistent leucopenia, which may be initially asymptomatic or present with symptoms of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"       \"Drug-induced neutropenia and agranulocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum sickness-like reaction, which presents with rash, fever, malaise, polyarthralgias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polyarthritis, beginning one to two weeks after first exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remainder of this topic focuses on the pathogenesis, diagnosis, and management of the most common form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    hypersensitivity (ie, an erythematous, macular rash starting on the trunk and spreading to the extremities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264013392\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific risk factors for uncomplicated dermatologic reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    have not been identified. The loading dose of clopidogrel given does not appear to impact the risk of hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23907478\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the most common form of dermatologic reaction is not known. The signs and symptoms are most suggestive of a T cell mediated mechanism, but other types of reactions (such as urticaria and angioedema) indicate that several mechanisms are possible.",
"   </p>",
"   <p>",
"    Allergy evaluations have been performed in a small number of studies in order to better define the pathogenesis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. In the largest study involving allergy testing, 62 patients underwent extensive allergy testing",
"    <strong>",
"     after",
"    </strong>",
"    they had been empirically treated through their clopidogrel reactions, completed therapy, and were free of the drug for at least four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"     2",
"    </a>",
"    ]. The testing was performed for the purpose of better defining the pathophysiology of clopidogrel reactions. Evaluation consisted of",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    and intradermal testing (with a clopidogrel solution of 0.75",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    for immediate-type reactions, as well as delayed (24 hours) reading of intradermal tests. Patch testing (clopidogrel 20 percent in petrolatum alba and 30 percent in water) was undertaken for delayed reactions, with readings at 72 hours and up to seven days, in an effort to better define the pathogenesis of these reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"     2",
"    </a>",
"    ]. Skin biopsy was obtained in some patients. Testing results were available for 42 patients. None had positive skin prick tests. Three had positive immediate (ie, &lt;30 minutes) intradermal tests, all of whom had presented with urticaria or angioedema. Patch testing was positive in 81 percent. However, all patients were managed in the same way. Of note, this study did not evaluate nonreacting patients or nonexposed individuals as controls to determine the optimal concentration for skin testing or the incidence of sensitization without clinical disease. This study is discussed more below. (See",
"    <a class=\"local\" href=\"#H270258018\">",
"     'Treating through'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264013267\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the most common form of cutaneous reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is made clinically, based upon suggestive signs and symptoms and appropriate time course [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. A thorough, full-body skin examination should be performed.",
"   </p>",
"   <p>",
"    Several laboratory tests may be helpful in excluding more serious forms of hypersensitivity reactions, since rash can be a feature of various types of reactions. The decision to obtain these tests should be based on the severity and clinical features of the patient&rsquo;s reaction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood counts with differential to evaluate for eosinophilia or cytopenias",
"     </li>",
"     <li>",
"      Liver function tests, blood urea nitrogen, and serum creatinine to detect liver or renal involvement",
"     </li>",
"     <li>",
"      Urinalysis to look for renal involvement, microscopic hematuria, or urine eosinophilia",
"     </li>",
"     <li>",
"      Skin biopsy for persistent, atypical, or severe cutaneous features",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23907639\">",
"    <span class=\"h2\">",
"     Allergy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy testing is not necessary for the diagnosis of straightforward dermatologic reactions and is often not readily available. Studies that have examined allergy testing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reactions are reviewed above. (See",
"    <a class=\"local\" href=\"#H23907478\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068280\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis primarily consists of reactions to other drugs. Many patients will have been recently exposed to other medications, such as beta blockers, ACE inhibitors, statins, agents used in procedures (radiographic contrast), and drugs eluting from coronary stents. Each of these agents has been implicated in maculopapular rashes. Delayed rashes to radiocontrast agents generally resolve without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. When the cause of an apparent drug eruption is unclear, initial interventions include discontinuing noncritical medications or changing to different agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264013274\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop a dermatologic reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , there are three options for future antiplatelet therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treating through without stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H270258018\">",
"       'Treating through'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and re-introducing it using a desensitization protocol (see",
"      <a class=\"local\" href=\"#H16154503\">",
"       'Desensitization'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and treating with a different antiplatelet agent (see",
"      <a class=\"local\" href=\"#H270258466\">",
"       'Alternate therapies'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial step in managing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    hypersensitivity reactions is deciding whether clopidogrel should be stopped because there are signs or symptoms of a potentially dangerous (ie, life-threatening) hypersensitivity reaction, or if it can be continued using one of the first two options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16155063\">",
"    <span class=\"h2\">",
"     Reactions that necessitate stopping clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until more is known about the pathogenesis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reactions, the author and editors of UpToDate suggest that clopidogrel be promptly discontinued and not re-introduced if any of the following signs or symptoms of a serious reaction is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms of anaphylaxis, such as flushing, urticaria, angioedema, accompanied by upper or lower airway compromise, bronchospasm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension (",
"      <a class=\"graphic graphic_figure graphicRef82831 \" href=\"UTD.htm?32/46/33514\">",
"       figure 1",
"      </a>",
"      ). Note that isolated urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema, without other symptoms, can represent a cutaneous reaction and these patients have been managed with ongoing therapy, as mentioned previously.",
"     </li>",
"     <li>",
"      Involvement of mucous membranes, as seen in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).",
"     </li>",
"     <li>",
"      Blistering or exfoliative skin rash, which is a feature of SJS, TEN, and other severe drug reactions.",
"     </li>",
"     <li>",
"      Involvement of organs other than the skin (eg, lungs, liver).",
"     </li>",
"     <li>",
"      Isolated fever unassociated with infection (suggesting drug fever).",
"     </li>",
"     <li>",
"      Persistent, severe hematologic changes, specifically eosinophilia, neutropenia, or thrombocytopenia. Note that some patients with dermatologic reactions have mild elevations in leukocytes, neutrophils,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelets or mild decrements in lymphocyte counts at the onset of the skin changes, so patient&rsquo;s cell counts should be evaluated carefully. (See",
"      <a class=\"local\" href=\"#H270258825\">",
"       'Most common signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258788\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    reactions are often successfully managed by clinicians with experience using this medication (cardiologists, neurologists) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/8\">",
"     8",
"    </a>",
"    ]. However, we suggest involving an allergy or dermatology specialist with experience in drug allergy if the patient demonstrates one or more of the signs and symptoms of a more serious type of reaction, which were mentioned above. Most desensitization procedures are carried out by allergy specialists. The opinion of an allergy specialist would also be helpful in cases of isolated urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema. As discussed previously, if a severe form of hypersensitivity is suspected, then changing to an alternative agent is the safest option. (See",
"    <a class=\"local\" href=\"#H270258802\">",
"     'More serious types of systemic reactions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16155063\">",
"     'Reactions that necessitate stopping clopidogrel'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258018\">",
"    <span class=\"h2\">",
"     Treating through",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of systemic glucocorticoids and antihistamines while continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy is referred to here as &ldquo;treating through&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. For patients with uncomplicated cutaneous reactions to clopidogrel and recently placed intracoronary stents, the authors and editors prefer treating through without stopping clopidogrel, rather than desensitization or changing to another therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10390303\">",
"    <span class=\"h3\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary advantage of treating through is that antiplatelet therapy is continued without interruption. This is particularly important for patients with recently placed intracoronary stents, in whom the risk for stent thrombosis is significantly increased if antiplatelet agents are stopped in the first days or weeks after stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 25 patients from the author&rsquo;s center, 21 had rash attributed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      as the primary presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/5\">",
"       5",
"      </a>",
"      ]. Two had rash accompanied by urticaria or angioedema, and three had isolated urticaria. None had other signs suggestive of anaphylaxis. Subjects were mostly outpatients, and received different combinations of antihistamines and glucocorticoids. The exact agents and doses were left to the discretion of the supervising physician, but patients most commonly received a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      six-day dose pack and some combination of first and second generation H1 antihistamines. If symptoms recurred, doses of glucocorticoids were increased and given for a longer period, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (10 mg daily) was added.",
"      <br/>",
"      <br/>",
"      In this series, 22 patients were successfully treated and tolerated clopidogrel, and three failed. Among the successfully treated patients, the mean duration of glucocorticoid treatment was 10&plusmn;8 days. One patient required 30 days of glucocorticoid therapy, and seven received additional drugs to suppress the reaction. Clopidogrel was discontinued in the three patients who failed because of angioedema, desquamating rash, and uncontrollable pruritus. The investigators devised a medication protocol based on this experience (",
"      <a class=\"graphic graphic_table graphicRef83462 \" href=\"UTD.htm?42/51/43835\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent, larger series, 62 patients were managed by treating through [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"       2",
"      </a>",
"      ]. Complete blood count and differential, platelet aggregation studies, and punch biopsy of affected skin were obtained. Presentations included generalized macular rash (49 subjects, confined to the trunk in 40), localized skin reaction, sometimes with peeling of the affected area (10 patients), and generalized urticaria or angioedema of the tongue or lips (three patients). Subjects with urticaria and angioedema developed symptoms within one day of drug introduction, while the other reactions began after a median of five days of therapy. Two patients reported fever and arthralgia. Some patients had elevations in leukocytes, neutrophils,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelets or depressed lymphocyte counts at the onset of symptoms (note that these hematologic changes are different from those described with hypersensitivity syndrome, which is characterized by thrombocytopenia and neutropenia). Eosinophilia was not observed. (See",
"      <a class=\"local\" href=\"#H270258802\">",
"       'More serious types of systemic reactions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      All patients were managed as outpatients, except one with angioedema, who was treated under observation in the intensive care unit [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"       2",
"      </a>",
"      ]. All were given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      : 30 mg twice daily for five days, followed by a decrease of 5 mg twice daily every third day for 15 more days. In addition, patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , 25 to 50 mg every six to eight hours, as needed for pruritus. All patients finished the 20-day course of prednisone, during which 95 percent had resolution of symptoms at 5&plusmn;2 days. All patients were able to complete the minimum required period of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      treatment (ie, four weeks for bare metal stents and 12 months for drug eluting stents). Four patients restarted clopidogrel at a later date and all had recurrences of hypersensitivity, which again responded to glucocorticoids and antihistamines. Once clopidogrel therapy was completed, allergy testing was performed on approximately two-thirds of the patients. Results were reviewed previously. (See",
"      <a class=\"local\" href=\"#H264013267\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16154503\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization is a procedure which",
"    <strong>",
"     temporarily",
"    </strong>",
"    alters the immune response to a medication and results in short-term tolerance, allowing the patient to receive an uninterrupted course of the medication safely. Drug desensitization renders mast cells unresponsive to the drug in question, although the exact immunologic mechanism is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/25\">",
"     25",
"    </a>",
"    ]. Drug desensitization is effective as long as the patient is receiving the drug, although the patient&rsquo;s sensitivity returns shortly after the drug is cleared from the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1531995\">",
"    <span class=\"h3\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary advantage of desensitization, compared with treating through, is that glucocorticoid therapy is not required. This may be important for some patients, provided they can be switched temporarily to another antiplatelet agent while desensitization is performed. Alternative antiplatelet agents are discussed below. (See",
"    <a class=\"local\" href=\"#H2067927\">",
"     'Protocol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1532089\">",
"    <span class=\"h3\">",
"     Types of reactions that have been managed with desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of reactions that have been managed with desensitization are the same as those managed with treating through. In the largest series, 24 consecutive patients who had undergone placement of an intracoronary stent were treated with desensitization. Patients were excluded if their",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reaction was anaphylaxis, angioedema involving the upper or lower airway, irritation or blistering of mucous membranes, or blistering or exfoliative skin rash. No patient had fever as part of their reaction. (See",
"    <a class=\"local\" href=\"#H270258802\">",
"     'More serious types of systemic reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2067927\">",
"    <span class=\"h3\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various desensitization protocols have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4,26-29\">",
"     4,26-29",
"    </a>",
"    ]. In the largest series of 24 patients, the protocol used required eight to nine hours and was performed in the outpatient setting, except when the patient was currently hospitalized for other reasons (",
"    <a class=\"graphic graphic_table graphicRef83638 \" href=\"UTD.htm?4/32/4621\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. An oral solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was prepared by finely crushing the drug into a liquid vehicle (see table legend). Other smaller series have described longer and shorter protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. No head-to-head comparisons of different protocols have been performed. With such small numbers, it is difficult to make strong recommendations concerning the safety of outpatient desensitization without there being availability of intensive treatment for anaphylaxis. In many instances outside of specialized research centers, such care can only be found in a hospital setting such as an intensive care unit or emergency department.",
"   </p>",
"   <p>",
"    Glucocorticoids are not required during desensitization and no other premedications were given in the 24-patient series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. Antihistamines and antileukotriene drugs were discontinued for seven days before the procedure. Beta blockers are usually withheld for one to two days prior, because beta blockade can interfere with the ability of the patient to respond to epinephrine, were it to be required during the desensitization.",
"   </p>",
"   <p>",
"    In the 24-patient series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was discontinued for five days before desensitization to allow the drug to wash out of the patient&rsquo;s body, during which time the rash usually resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. This wash out period was felt to be important, since patients who did not complete the wash out period were more likely to react during the desensitization, although it is also possible that this reflected more severe hypersensitivity in those patients whose symptoms persisted.",
"   </p>",
"   <p>",
"    During the wash out period, alternative antiplatelet agents are given to patients with recently placed intracoronary stents to prevent stent thrombosis. The safest alternative antiplatelet agent during this process is unclear. In the 24-patient series, subjects were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    250 mg twice daily for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. Another option is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    if the patient does not have relative contraindications (prior TIA or stroke, or if weight &lt;60 kg). In either case, cross-sensitivity is possible, and the patient should be monitored closely. (See",
"    <a class=\"local\" href=\"#H270258466\">",
"     'Alternate therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once desensitization has been performed, patients are obligated to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    daily for as long as the drug is needed. If several doses are missed (the refractory period is not precisely defined), the patient will again be at risk for recurrence of the hypersensitivity reaction and desensitization should be performed again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2067858\">",
"    <span class=\"h3\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the series of 24 patients, all were successfully desensitized, although one patient required continued antihistamines and two required repetition of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"     4",
"    </a>",
"    ]. Only four patients had reactions (all cutaneous) during desensitization. All patients were able to continue therapy for six months, although one had mild intermittent symptoms that were managed with antihistamines, and two were noncompliant and required repeat desensitization. Thus, desensitization is a highly successful although more complicated approach, compared to suppressing the reaction and treating through.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258466\">",
"    <span class=\"h1\">",
"     ALTERNATE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to managing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    hypersensitivity reaction is simply switching to a different antiplatelet agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . The alternatives to clopidogrel for management of various cardiovascular disorders are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H14#H14\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Hypersensitivity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H8268853#H8268853\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Use of alternative antiplatelet agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17286196\">",
"    <span class=\"h2\">",
"     Cross-reactivity among drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited studies of potential cross-reactivity between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and related drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2,31-33\">",
"     2,31-33",
"    </a>",
"    ]. Briefly, evidence suggests that up to one-third of patients with reactions to clopidogrel will have similar reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . Less is known about cross-reactivity between clopidogrel and other drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 76 patients with hypersensitivity or hematologic reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      found that about 27 percent of patients developed a similar (although not more severe) reaction when given the other agent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the study of 62 patients discussed above, 81 percent had positive patch tests to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"       2",
"      </a>",
"      ]. Within this group, 26 percent also reacted to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      , 18 percent to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      , and 9 percent, to all three drugs. However, none of the patients were treated with ticlopidine or prasugrel, so clinical cross-reactivity and the correlation between a positive test and a clinical reaction to the drug was not established.",
"     </li>",
"     <li>",
"      A case report described a patient who developed rash to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in the past and had a similar reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26232/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270258678\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common form of hypersensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      presents as an erythematous, macular rash starting on the trunk and spreading to the extremities, beginning approximately a week after the initiation of clopidogrel. The pathogenesis is not known although a lymphocyte mediated response is suspected. (See",
"      <a class=\"local\" href=\"#H17286109\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H264013392\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      has also been implicated in a variety of potentially life-threatening types of hypersensitivity reactions, some of which include rash. (See",
"      <a class=\"local\" href=\"#H270258802\">",
"       'More serious types of systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      hypersensitivity is made clinically, based upon appropriate signs, symptoms, and timing. Laboratory studies are performed to exclude more serious types of reactions. (See",
"      <a class=\"local\" href=\"#H264013267\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with uncomplicated cutaneous reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , there are three options for future antiplatelet therapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treating through without stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H270258018\">",
"       'Treating through'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and re-introducing it using a desensitization protocol (see",
"      <a class=\"local\" href=\"#H16154503\">",
"       'Desensitization'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and treating with a different antiplatelet agent (see",
"      <a class=\"local\" href=\"#H270258466\">",
"       'Alternate therapies'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with uncomplicated cutaneous reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and recently placed intracoronary stents, we suggest treating through without stopping clopidogrel, rather than desensitization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with uncomplicated cutaneous reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      who require the drug for secondary prevention of stroke or other manifestations of cardiovascular disease, AND who are at risk for complications of glucocorticoid therapy or wish to avoid glucocorticoids for other reasons, we suggest stopping clopidogrel and re-introducing it using a desensitization protocol, rather than treating through (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/1\">",
"      Lokhandwala J, Best PJ, Henry Y, Berger PB. Allergic reactions to clopidogrel and cross-reactivity to other agents. Curr Allergy Asthma Rep 2011; 11:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/2\">",
"      Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011; 58:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/3\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/4\">",
"      von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/5\">",
"      Campbell KL, Cohn JR, Fischman DL, et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol 2011; 107:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/6\">",
"      Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart 2004; 90:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/7\">",
"      Fischer TC, Worm M, Groneberg DA. Clopidogrel-associated angioedema. Am J Med 2003; 114:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/8\">",
"      Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Rev Clin Pharmacol 2010; 3:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/9\">",
"      Ellerbroek JC, Cleveland MG. Clopidogrel-associated acute generalized exanthematous pustulosis. Cutis 2011; 87:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/10\">",
"      Jeung YJ, Lee JY, Oh MJ, et al. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010; 2:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/11\">",
"      Andersohn F, Hagmann FG, Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004; 90:e57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/12\">",
"      Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/13\">",
"      Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005; 80:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/14\">",
"      Andres E, Perrin AE, Alt M, et al. Febrile pancytopenia associated with clopidogrel. Arch Intern Med 2001; 161:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/15\">",
"      Meyer B, Staudinger T, Lechner K. Clopidogrel and aplastic anaemia. Lancet 2001; 357:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/16\">",
"      Trivier JM, Caron J, Mahieu M, et al. Fatal aplastic anaemia associated with clopidogrel. Lancet 2001; 357:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/17\">",
"      Akcay A, Kanbay M, Agca E, et al. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother 2004; 38:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/18\">",
"      McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother 2003; 37:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/19\">",
"      Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol 2003; 56:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/20\">",
"      Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopdogrel after a positive skin test (Abstract 44). Ann Allergy Asthma Immunol 2005; 94:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/21\">",
"      Gu&eacute;ant-Rodriguez RM, Romano A, Barbaud A, et al. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des 2006; 12:3359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/22\">",
"      Hasdenteufel F, Waton J, Cordebar V, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. J Allergy Clin Immunol 2011; 128:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/23\">",
"      Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/24\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/25\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/26\">",
"      Walker NE, Fasano MB, Hobbs RA, Horwitz PA. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Crit Pathw Cardiol 2007; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/27\">",
"      Lee-Wong M, Gadhvi D, Resnick D. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006; 96:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/28\">",
"      Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/29\">",
"      Fajt M, Petrov A. Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen. Ann Pharmacother 2010; 44:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/30\">",
"      Sanchez-Lopez J, Mu&ntilde;oz-Cano R, Bartra J, et al. Desensitization to clopidogrel: a growing need. Allergy 2010; 65:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/31\">",
"      Lokhandwala JO, Best PJ, Butterfield JH, et al. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv 2009; 2:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/32\">",
"      van Werkum JW, Braber TL, Verheggen PW, Van Der Have-Roeffel SM. Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. Platelets 2011; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26232/abstract/33\">",
"      Raccah BH, Shalit M, Danenberg HD. Allergic reaction to prasugrel and cross-reactivity with clopidogrel. Int J Cardiol 2012; 157:e48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82798 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26232=[""].join("\n");
var outline_f25_39_26232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H270258678\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264013215\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17286097\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17286109\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270258825\">",
"      Most common signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684933\">",
"      Other cutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270258802\">",
"      More serious types of systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264013392\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23907478\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264013267\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23907639\">",
"      Allergy testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2068280\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264013274\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16155063\">",
"      Reactions that necessitate stopping clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270258788\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270258018\">",
"      Treating through",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10390303\">",
"      - Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16154503\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1531995\">",
"      - Advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1532089\">",
"      - Types of reactions that have been managed with desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2067927\">",
"      - Protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2067858\">",
"      - Success rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H270258466\">",
"      ALTERNATE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17286196\">",
"      Cross-reactivity among drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H270258678\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/82798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/82798|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/46/33514\" title=\"figure 1\">",
"      Clinical criteria for diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/82798|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/23/32118\" title=\"picture 1\">",
"      Clopidogrel generalized exanthema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/82798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/52/23371\" title=\"table 1\">",
"      Anaphylaxis signs symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/51/43835\" title=\"table 2\">",
"      Protocol for treating through clopidogrel hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/32/4621\" title=\"table 3\">",
"      Clopidogrel desensitization protocol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=related_link\">",
"      Acute generalized exanthematous pustulosis (AGEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26233="Management of diabetes mellitus in hospitalized patients";
var content_f25_39_26233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of diabetes mellitus in hospitalized patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26233/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26233/contributors\">",
"     Silvio E Inzucchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26233/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26233/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/39/26233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 1 or type 2 diabetes mellitus are frequently admitted to a hospital, usually for treatment of conditions other than the diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one study, 25 percent of patients with type 1 diabetes and 30 percent with type 2 diabetes had a hospital admission during one year; patients with higher values for hemoglobin A1C (A1C) were at highest risk for admission [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of diabetes rises with increasing age, as does the prevalence of other diseases; both factors increase the likelihood that an older person admitted to a hospital will have diabetes.",
"   </p>",
"   <p>",
"    Much of what was formerly done in hospital, including many surgical procedures, complex diagnostic testing, or treatment of community-acquired infections, is now done in a clinic or at home. However, the presence of diabetes might precipitate admission of a patient who would otherwise be treated as an outpatient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/3\">",
"     3",
"    </a>",
"    ]. Whether in hospital or not, glycemic control is likely to become unstable in these patients because of the stress of the illness or procedure, the concomitant changes in dietary intake and physical activity, and the frequent interruption of the patient's usual antihyperglycemic regimen.",
"   </p>",
"   <p>",
"    Once in the hospital, the length of stay and cost are greater for patients with diabetes than for those without it [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Efficient treatment of diabetes in hospital may be an important factor in limiting the costs of care. However, as mentioned below, firm data on optimal in-hospital treatment are sparse.",
"   </p>",
"   <p>",
"    The treatment of patients with diabetes who are admitted to the general medical wards of the hospital for a procedure or intercurrent illness is reviewed here. The treatment of hyperglycemia in critically ill patients, the perioperative management of diabetes, and the treatment of complications of the diabetes itself, such as diabetic ketoacidosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS IN THE HOSPITAL SETTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goals in patients with diabetes needing hospitalization are to minimize disruption of the metabolic state, prevent an untoward result, and return the patient to a stable glycemic balance as quickly as possible. These goals are not always easy to achieve. On the one hand, the stress of the acute illness tends to raise blood glucose concentrations. On the other hand, the anorexia that often accompanies illness or the need for fasting before a procedure tends to do the opposite. Because the net effect of these countervailing forces is not easily predictable in a given patient, the target blood glucose concentration is usually higher than when the patient is stable.",
"   </p>",
"   <p>",
"    Uncertainty regarding goal blood glucose concentration is compounded by the paucity of controlled trials on the benefits and risks of \"loose\" or \"tight\" glycemic control in hospitalized patients, with the exception of patients who are critically ill or have had an acute myocardial infarction (MI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the goals are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid hypoglycemia",
"     </li>",
"     <li>",
"      Avoid severe hyperglycemia, volume depletion, and electrolyte abnormalities",
"     </li>",
"     <li>",
"      Ensure adequate nutrition",
"     </li>",
"     <li>",
"      Assess patient educational needs and address deficiencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Critical to achieving these goals is the frequent measurement of glucose, often in capillary blood, with a method that is known to be reliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H7#H7\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Sources of error in SMBG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Avoidance of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia should be avoided if at all possible. Although relatively brief and mild hypoglycemia does not usually have clinically significant sequelae, hospitalized patients are particularly vulnerable to severe, prolonged hypoglycemia since they may be unable to sense or respond to the early warning signs and symptoms of low blood glucose.",
"   </p>",
"   <p>",
"    Hypoglycemia (ie, serum glucose concentration &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.9",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    can be harmful, due to the effects of counter-regulatory hormones, especially catecholamines, which may possibly induce arrhythmias and other cardiac events. This is especially true in the elderly and those with preexisting ischemic heart disease. If the blood glucose falls to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    transient cognitive deficits may also ensue, which can result in falls or aspiration. In a retrospective cohort study of over 2500 patients with diabetes hospitalized in the general wards, inpatient mortality was significantly higher for patients with at least one hypoglycemic (&le;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    episode [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of hypoglycemia in sulfonylurea and insulin-treated patients in the hospital include continued antihyperglycemic therapy when caloric intake is stopped or reduced, use of a standard \"sliding scale\" of insulin without consideration of the patient's specific circumstances, attempts to provide \"tight\" glycemic control intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/6\">",
"     6",
"    </a>",
"    ], errors in insulin dosing, and implementation of intensive insulin therapy in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Avoidance of hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious hyperglycemia should be avoided. It is a long-standing clinical observation that patients with diabetes are more susceptible to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, immune and neutrophil function is impaired during marked hyperglycemia. However, whether or not hyperglycemia imposes an independent risk for infection is a controversial issue. Most of the studies addressing this question have focused on the risk of postoperative infection (and especially sternal wound infection) following coronary artery bypass grafting (CABG) with mixed results. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to infections in persons with diabetes mellitus\", section on 'Are diabetics more susceptible to infection?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, hyperglycemia can cause volume and electrolyte disturbances mediated by osmotic diuresis and may also result in caloric and protein loss in under-insulinized patients. These are clearly undesirable in ill patients and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glycemic targets",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Non-critically ill",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is adequate experimental and observational data to recommend avoidance of marked hyperglycemia in patients with or at risk for infection, although the precise glycemic target or threshold for non-critically ill patients has not yet adequately been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of data from clinical trials, the optimal blood glucose goal for non-critically ill hospitalized patients can only be approximate. We agree with the consensus statement by the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/11\">",
"     11",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ADA/AACE",
"    </span>",
"    recognizes the lack of evidence for specific glycemic goals in non-critically ill patients and suggests pre-meal glucose goals of &lt;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for general hospitalized patients, with all random glucoses &lt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. More stringent goals may be appropriate for stable patients with previous good glycemic control, and the goal should be set somewhat higher for older patients and those with severe comorbidities where the heightened risk of hypoglycemia may outweigh any potential benefit.",
"   </p>",
"   <p>",
"    A reasonable glycemic goal to avoid hypoglycemia is to achieve fasting blood glucose concentrations no lower than 90 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.0 to 5.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    this will usually provide a reasonable \"cushion\" in case the concentration falls further than expected. In general, all glucose levels should be kept below 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to avoid dehydration, caloric loss, glycosuria, and to reduce the risk of infection and, although rare, ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Critically ill",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate targets for patients with pre-existing diabetes mellitus who are critically ill (intensive care unit [ICU] setting) have not been firmly established. Some trials showed that achieving normoglycemia (80 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.4 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in cardiac surgery patients or those requiring postoperative surgical ICU settings may reduce mortality. However, subsequent trials in mixed populations of critically ill patients did not show a benefit of targeting a blood glucose of 80 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.4 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    These trials are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link&amp;anchor=H8#H8\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\", section on 'Mixed patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of the patients in these studies were not previously known to have diabetes, but developed postoperative hyperglycemia during the course of their ICU care. A subgroup analysis of patients with pre-existing diabetes from two randomized trials assessing tight control in the ICU setting raised the possibility that the potential benefits of tight control do not extend to patients with known diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/13\">",
"     13",
"    </a>",
"    ]. These preliminary findings highlight the need for prospective studies to determine whether the apparent benefits of tight control apply to patients with known diabetes.",
"   </p>",
"   <p>",
"    For the majority of critically ill patients, the American Diabetes Association and the American College of Endocrinology recommend a blood glucose target of 140 to 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 10.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Achieving this goal will usually require an insulin infusion, which should be initiated when glucose is no greater than 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.0",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The data supporting these glycemic goals are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that suboptimal glycemic control in diabetic patients and stress-induced hyperglycemia in nondiabetic patients are associated with worse outcomes after acute MI and that better glycemic control may be beneficial in some individuals.",
"   </p>",
"   <p>",
"    Although clinical trial data assessing this issue are sparse, the American Heart Association recommends the use of an insulin infusion when glucose values are &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with an MI and a complicated course. The data supporting these conclusions and glycemic goals are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\", section on 'Acute glucose targets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT OF HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperglycemia in hospitalized patients depends upon the type of diabetes, the patient's current blood glucose concentrations, prior treatment, the clinically assessed severity of illness, and the expected caloric intake during the acute episode (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/1,4,14,15\">",
"     1,4,14,15",
"    </a>",
"    ]. At the time of admission or before an outpatient procedure or treatment, blood glucose should be measured and the result known. In addition, glucose monitoring should be continued so that appropriate action may be taken. The frequency of measurement depends upon the patients' status, the results of earlier measurements, and the steps taken as a result of those measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Types of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients will have type 2 diabetes, many will require insulin therapy, if only temporarily during inpatient admissions. In such patients, insulin may be given subcutaneously with an intermediate-acting insulin, such as NPH, or a long-acting insulin, such as glargine or detemir, combined with premeal rapid or short-acting insulin in patients who are eating regular meals (ie, a \"basal-bolus\" regimen) or as an intravenous infusion. The key point is that the patient should have at least a small amount of insulin circulating at all times, which will significantly increase the likelihood of controlling blood glucose levels during illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sliding-scale insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of the \"sliding scale\" of insulin administration for hospitalized patients began during the era of urine glucose testing and it increased after the introduction of rapid capillary blood glucose testing in the last two to three decades. However, there are few data to support its benefit and some evidence of potential harm when the \"sliding scale\" is applied in a rote fashion, that is, when all patients receive the same orders and, importantly, when the sole form of insulin administered is rapid-acting insulin every four to six hours without underlying provision of basal insulin.",
"   </p>",
"   <p>",
"    This was illustrated in an observational study of 171 patients with diabetes who were admitted to a university hospital, 130 of whom (76 percent) were placed on a sliding scale insulin regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/16\">",
"     16",
"    </a>",
"    ]. Sliding scale insulin regimens when administered alone were associated with a threefold higher risk of hyperglycemic episodes as compared with no therapy (relative risk 2.85 for \"aggressive\" scales, beginning at blood glucose 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8.3",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    and 3.25 for \"conservative\" scales, beginning at blood glucose 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L;",
"    </span>",
"    p&lt;0.05]). Thus, in this observational study, the use of sliding scale insulin alone provided no benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Correction insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying doses of short-acting or rapid-acting insulin can be added to usual premeal short or rapid-acting insulin in patients on basal-bolus regimens to correct premeal glucose excursions. In this setting, the additional insulin is referred to as \"correction insulin\" (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ). The dose of correction insulin should be individualized based upon relevant patient characteristics such as previous level of glucose control, previous insulin requirements and, if possible, the carbohydrate content of meals. When administered prior to meals, the type of correction insulin (eg, short-acting or rapid-acting) should be the same as the usual premeal insulin.",
"   </p>",
"   <p>",
"    Correction insulin alone may also be used as initial insulin therapy or as a dose-finding strategy in patients with type 2 diabetes previously treated at home with diet or an oral agent, who will not be eating regularly during hospitalization. It is typically administered every six hours as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ). It can be given at bedtime in modest doses to correct marked hyperglycemia (&gt;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [16.6",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    However, if the patient is eating and finger stick glucoses are consistently elevated (&gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10.0",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    a combination of intermediate or long-acting insulin and premeal short or rapid-acting insulin (ie, a basal-bolus regimen) should be initiated (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Insulin infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with type 1 or type 2 diabetes admitted to the general medical wards can be treated with subcutaneous insulin. However, many practitioners institute intravenous insulin therapy for patients with type 1 diabetes, especially those undergoing long and difficult surgery, or those who will be expected to have significantly curtailed oral nutritional intake for several days post-operatively, because changes of dose have a more immediate effect compared with subcutaneous therapy. However, there are little data showing that intravenous insulin is superior to subcutaneous insulin.",
"   </p>",
"   <p>",
"    In addition, the safe implementation of insulin infusion protocols requires frequent monitoring of blood glucose, which is not typically available on a general medical ward. Practical considerations including skill and availability of the nursing staff may impact the choice of delivery; complex intravenous regimens may be dangerous where nurses are short-staffed or inexperienced. Thus, insulin infusions are typically used in critically ill ICU patients, rather than in patients on the general medical wards of the hospital.",
"   </p>",
"   <p>",
"    There is a lack of consensus on how to best deliver intravenous insulin infusions, and individual patients may require different strategies. The best protocols take into account not only the prevailing blood glucose, but also its rate of change and the current insulin infusion rate. Several published insulin infusion protocols appear to be both safe and effective, with low rates of hypoglycemia, although most have been validated only in the intensive care unit setting, where the nurse to patient ratio is higher than on the general medical and surgical wards [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. There are few published reports on such protocols outside of the critical care setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the course of giving an intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    infusion, we recommend using about half the usual total daily dose of insulin, divided into hourly increments until the trend of blood glucose values is known, and then adjusting the dose accordingly. A reasonable regimen usually involves a continuous insulin infusion at a rate of 1 to 5 units of regular insulin per hour; within this range the dose of insulin is increased or decreased according to the patient's usual insulin dose. In patients who are not eating, concomitant glucose infusion is necessary to provide some calories, reduce protein loss, and decrease the risk of hypoglycemia; some combine insulin and glucose in a single infusion, while others give these via separate infusions for more flexible control.",
"   </p>",
"   <p>",
"    When the patient receiving intravenous insulin is more stable and the intercurrent event has passed, the prior insulin regimen can be resumed, assuming that it was effective in achieving glycemic goals. Because of the short half-life of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , the first dose of subcutaneous insulin must be given before discontinuation of the intravenous insulin infusion. If intermediate or long-acting insulin is used, it should be given two to three hours prior to discontinuation, whereas short or rapid-acting insulin should be given one to two hours prior to stopping the infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients with type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with type 2 diabetes depends upon previous therapy and the current blood glucose concentration. Any patient who takes insulin before hospitalization should receive insulin throughout the episode (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a patient previously under reasonable control (A1C &le;8 percent) at home with diet or an oral agent, correction insulin alone (varying doses of short or rapid-acting insulin) is a good initial treatment strategy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Correction insulin'",
"    </a>",
"    above.) If the patient is unable to eat, oral agents should be discontinued. In patients who are eating and who do not have contraindications to their oral agent, oral agents may be continued (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Patients treated with oral agents'",
"    </a>",
"    below). However, if contraindications develop or if blood glucoses are persistently elevated (&gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10.0",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    these drugs should be discontinued and a more formal and comprehensive insulin regimen prescribed (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Therapy should be returned to the patients' previous regimens (assuming that it had been effective) as soon as possible after the acute episode, usually as soon as the patient has resumed eating his or her usual diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diet treated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetic patients treated by diet alone who are to have minor surgery or an imaging procedure, or who have a non-critical acute illness that is expected to be short-lived, will typically need no specific anti-hyperglycemic therapy. Nevertheless, frequent blood glucose monitoring is warranted to prevent serious hyperglycemia from being unrecognized. The measurement system used should be standardized to ensure reasonable accuracy and precision.",
"   </p>",
"   <p>",
"    Insulin therapy should be instituted if the preprandial blood glucose concentration exceeds 150 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3 to 11.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    but the patient should be informed that insulin may not be necessary after the episode is over. Some have proposed more rigid glucose thresholds for initiating insulin therapy, such as 110 to 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [6.1 to 8.3",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    but these recommendations stem from studies conducted in critically ill patients.",
"   </p>",
"   <p>",
"    In patients who are not eating, correction insulin (as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    ) can be administered every six hours as a sliding scale (",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Correction insulin'",
"    </a>",
"    above). However, if the patient is eating and finger stick glucoses are consistently elevated (&gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10.0",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    a basal-bolus insulin regimen should be initiated. Insulin requirements can be estimated based upon a patient's body weight (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    ). Alternatively, requirements can be based upon the total number of units of correction insulin administered over the course of a hospital day. Fifty percent of the total daily dose can be given as basal insulin and the remaining 50 percent can be given in equally divided doses prior to meals (one-third prior to each meal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Patients treated with oral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, insulin is the preferred treatment for hyperglycemia in hospitalized patients previously treated with oral agents. However, there are some circumstances where insulin may not be necessary. As an example, in patients who are well controlled on their outpatient regimen, who are eating, and in whom no change in their medical condition or nutritional intake is anticipated, oral agents may be continued, as long as new contraindications are neither present nor anticipated during the hospital admission.",
"   </p>",
"   <p>",
"    If a patient was previously eating but is unable to eat after the evening meal in preparation for a procedure the next morning, oral hypoglycemic drugs should be omitted on the day of a procedure (surgical or diagnostic). If procedures are arranged as early in the day as possible, anti-hyperglycemic therapy and food intake can simply then be shifted to later in the day.",
"   </p>",
"   <p>",
"    If the illness requiring admission is more severe (eg, an infection requiring hospitalization), hyperglycemia is more likely, even when there is decreased food intake, and most acutely ill patients will need insulin. In this setting, oral agents should be discontinued. Overt hyperglycemia (&gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in patients previously treated with oral agents can be treated briefly with intermittent subcutaneous doses of regular (every six hours) or rapid-acting (every four to six hours) insulin, provided the blood glucose is not severely elevated, responds well to the insulin, and the problem lasts only a day or two at most. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Correction insulin'",
"    </a>",
"    above.) However, a more formal and comprehensive insulin regimen, including some form of basal insulin, is usually preferred when hyperglycemia persists (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Oral agents should never be administered to patients who are not eating. In addition, many oral agents have specific contraindications that may occur in hospitalized patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      is contraindicated in situations in which renal function",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemodynamic status is either impaired or threatened, due to the increased risk of lactic acidosis. Examples would include patients with acute cardiac or pulmonary decompensation, acute renal failure, dehydration, sepsis, urinary obstruction, or in those undergoing surgery or radiocontrast studies. Given the typical case mix in most acute care hospitals, in more cases than not, metformin should probably be discontinued at least temporarily. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link&amp;anchor=H9#H9\">",
"       \"Metformin in the treatment of diabetes mellitus\", section on 'Predisposing factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The thiazolidinediones (TZDs, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      ) are associated with peripheral edema and should be avoided in patients with heart failure. If the question of ventricular dysfunction is raised during a hospitalization, TZDs should be held until the situation is clarified. The anti-hyperglycemic effect of this drug class extends for several weeks after discontinuation (as does the fluid-retaining effect), so that temporary interruption of therapy should have little effect on glycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sulfonylureas (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"       glimepiride",
"      </a>",
"      ) are associated with hypoglycemia that can be severe and prolonged. Although they may be continued during the hospitalization in stable patients who are expected to eat regularly, unexpected alterations in meal intake will increase the risk for hypoglycemia.",
"      <br/>",
"      <br/>",
"      On balance, sulfonylureas should usually be discontinued, at least temporarily, in the hospitalized patient. In particular, sulfonylureas should be discontinued in the patient with acute myocardial infarction because there is some concern that they may adversely affect ischemic preconditioning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link&amp;anchor=H6#H6\">",
"       \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\", section on 'Association with coronary disease outcomes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"       \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-sulfonylurea secretagogues (meglitinides, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"       nateglinide",
"      </a>",
"      ) work similarly to the sulfonylureas, but have a shorter duration of action. As a result, these prandial-administered drugs may have a theoretical advantage in hospitalized patients, but should also be used cautiously, including in those with acute ischemic heart disease events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"       \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alpha-glucosidase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"       acarbose",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"       miglitol",
"      </a>",
"      ) are generally used infrequently and are not typically on hospital formularies. Moreover, these inhibitors of intestinal carbohydrate absorption are only effective in patients who are eating and therefore have a limited role in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"       \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dipeptidyl peptidase IV (DPP-IV) inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=see_link\">",
"       saxagliptin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      ) exert their effect mainly in the postprandial setting. As a result, they have no role in patients who are not eating. DPP-IV inhibitors have not been tested in the acute care setting and typically are not used in the hospital. Sitagliptin and saxagliptin require dose reduction in the setting of impaired renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"       \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucagon-like peptide 1 (GLP-1) agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      ) may result in nausea and are also mainly effective for postprandial glucose control. As a result, their use should probably be avoided in the acute setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H4#H4\">",
"       \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Exenatide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Patients treated with insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin therapy should be continued in all patients already taking it to maintain a reasonably constant basal level of circulating insulin. Failing this, severe hyperglycemia or ketoacidosis can occur, even in patients labeled as having type 2 diabetes but who have become significantly insulin deficient over a prolonged disease course.",
"   </p>",
"   <p>",
"    In the non-acute hospital setting and when the patient is eating regularly, basal insulin (NPH or detemir every 12 to 24 hours or glargine every 24 hours) in combination with short or rapid-acting prandial (bolus) insulin (regular, lispro, aspart, glulisine) is generally effective for patients receiving insulin at home or for patients with poorly controlled blood sugars previously managed with diet or oral agents (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Different",
"    <span class=\"nowrap\">",
"     basal/bolus",
"    </span>",
"    regimens are similarly effective in reducing A1C concentrations, when insulin doses are titrated to achieve glycemic goals. As an example, in a trial of",
"    <span class=\"nowrap\">",
"     detemir/aspart",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     NPH/regular",
"    </span>",
"    in 130 hospitalized patients, there was no difference in glycemic control or frequency of hypoglycemia between the two regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some studies, treatment with such a basal-bolus insulin regimen was associated with better glycemic outcomes than sliding-scale insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, in one open-label randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    supplemented with preprandial glulisine versus sliding-scale insulin, a greater proportion of patients treated with the basal-bolus regimen achieved target glucose values (66 versus 38 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in this study, the mean daily dose of insulin was more than threefold higher in the basal-bolus treated patients than in those assigned to sliding-scale, likely reflecting a failure to titrate the doses of sliding-scale insulin.",
"   </p>",
"   <p>",
"    When food intake is diminished or stopped completely in a patient treated with insulin, short or rapid-acting insulin is typically discontinued, and the dose of",
"    <span class=\"nowrap\">",
"     intermediate/long-acting",
"    </span>",
"    insulin is reduced. If an episode is clearly short-lived (eg, a procedure done in the early morning), subcutaneous insulin (usual dose of short-acting and",
"    <span class=\"nowrap\">",
"     intermediate/long-acting)",
"    </span>",
"    and breakfast can simply be delayed until after the episode.",
"   </p>",
"   <p>",
"    However, if the episode is longer (eg, an operation done in the afternoon with no food intake for the entire day), the patient should not receive any short or rapid-acting insulin. That morning's dose of subcutaneous intermediate (NPH) or long-acting (glargine, detemir) insulin should be administered at approximately one-half to two-thirds of the usual dose and administered at the usual time, unless hypoglycemia is already present. The subcutaneous dose of intermediate (NPH) or long-acting (glargine, detemir) insulin given the night before may not require any adjustment if previously dosed properly. However, another approach is to reduce the evening dose by approximately 20 percent to minimize the risk of hypoglycemia the next morning. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient who takes 30 units of NPH insulin in the morning might be given 15 to 20 units in the morning.",
"     </li>",
"     <li>",
"      A patient who takes 30 units of glargine in the evening and lispro insulin before each meal might take the same dose of glargine the night before admission but omit the usual dose of pre-prandial rapid-acting insulin. An alternative approach is to reduce the evening glargine by approximately 20 percent (eg, give 24 units).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both of these cases, small amounts of short or rapid-acting insulin can be administered every six hours to correct hyperglycemia (ie, glucose &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Intravenous glucose (at about 3.75 to 5",
"    <span class=\"nowrap\">",
"     g/hour,",
"    </span>",
"    eg, 5 percent dextrose at 75 to 100 cc per hour) should be given to limit the metabolic changes of starvation.",
"   </p>",
"   <p>",
"    Once the patient is taking a normal diet, the usual at-home regimen can be restarted, as long as it was resulting in good glucose control. If altered nutritional intake is present, reduced doses of insulin will be required, starting with doses similar to those administered in the pre-procedure setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients with type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 1 diabetes have an absolute requirement for insulin at all times, whether or not they are eating, to prevent ketosis. The doses of insulin needed are usually lower than in patients with type 2 diabetes, since most of the former do not have insulin resistance. However, their blood glucose concentrations tend to fluctuate more during the course of the illness or procedure. It is important to avoid hypoglycemia, even if the consequence is a temporary modest rise in the blood glucose concentration.",
"   </p>",
"   <p>",
"    Insulin can be given either subcutaneously or intravenously. Algorithms for glycemic management of non-fasting and fasting patients with type 1 diabetes who are not critically ill are shown for subcutaneous dosing regimens (",
"    <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient is receiving nothing by mouth, the administration of basal insulin is still required. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a patient who usually takes 24 units of NPH and 4 units of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in the morning, one-half to two-thirds (12 to 16 units) of the usual morning dose of NPH insulin can be given (if the morning blood glucose value is not too low, ie, is at least 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [6.7",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"      Short or rapid-acting insulin should not be given, except if significant hyperglycemia (&gt;200 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      is found in the morning. In such cases, only small doses (one to four units) should be given with the goals of reducing the blood glucose level to &lt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and avoiding hypoglycemia during the ongoing fast.",
"     </li>",
"     <li>",
"      For a patient who usually takes 20 units of glargine every evening and short-acting insulin before each meal (dose based upon prevailing blood sugar and carbohydrate content of meal), the usual dose of glargine can be continued. An alternative approach is to reduce the dose of glargine by 20 percent (eg, give 16 units) to minimize the risk of hypoglycemia that might require oral ingestion of calories and thereby delay the planned procedure. Short-acting insulin should not be given, unless significant hyperglycemia is noted, as described above.",
"     </li>",
"     <li>",
"      For a patient treated with a continuous insulin infusion via a pump, the basal insulin can be continued at the usual rate, or the overnight basal rate may be reduced by 20 percent to minimize the risk of hypoglycemia the next morning. No boluses would be administered until the patient is able to eat. Since nursing staff are not always familiar or comfortable with the use of insulin pumps, patients should be alert enough to manage their pump therapy. In addition, vigilance regarding pump catheter placement is necessary. Catheters may inadvertently be dislodged during transfers in the operating room or in bed, and if the patient is not alert enough to provide self-care, the health care providers should consider changing to conventional injection therapy until the patient is able to manage pump therapy again.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all of these cases, blood glucose is measured every two to three hours until the meal is eaten. Small amounts of short or rapid-acting insulin can be administered every six hours to correct hyperglycemia (ie, glucose &gt;150 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8.3 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Intravenous glucose (at about 3.75 to 5",
"    <span class=\"nowrap\">",
"     g/hour,",
"    </span>",
"    eg, 5 percent dextrose at 75 to 100 cc per hour) should be given to limit the metabolic changes of starvation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28178?source=see_link\">",
"     \"Illustrative cases of intensive insulin therapy in special situations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients receiving enteral or parenteral feedings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) or tube feeds (bolus or continuous) require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     TPN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients receiving TPN, insulin is typically administered with the nutrition. To determine the correct dose of insulin to add to the TPN fluid, a separate infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    can be used initially. When glucoses have reached goal, the total daily dose of regular insulin provided by the insulin drip is calculated; 80 percent of this amount is added to the TPN fluid as regular insulin. The amount of insulin can be titrated based upon glucose monitoring.",
"   </p>",
"   <p>",
"    If TPN is interrupted, most patients with type 2 diabetes can be followed with careful glucose monitoring. Insulin should be administered if hyperglycemia occurs. In patients with type 1 diabetes, hyperglycemia will occur and can result in ketosis if all insulin is withheld. Thus, patients with type 1 diabetes require insulin when the TPN is interrupted. The amount and type of insulin depend upon the anticipated duration of the interruption. Because of the potential for inadvertent discontinuation of insulin therapy if TPN is interrupted, many clinicians recommend giving some of the basal insulin as an injection (eg, 50 percent) in patients with type 1 diabetes, independent of the insulin included in the TPN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Enteral feedings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients receiving continuous enteral feeds, the total daily dose of insulin could be administered as basal insulin alone (once daily glargine or twice daily detemir or NPH). However, if the enteral feeds are unexpectedly discontinued, hypoglycemia may occur. Thus, a safer approach may be to administer approximately 50 percent of the total daily insulin dose as basal insulin and 50 percent as prandial (short or rapid-acting) insulin, which is given every four (rapid-acting insulin) to six (short-acting insulin) hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/21\">",
"     21",
"    </a>",
"    ]. A similar ratio of basal to prandial insulin can be used for patients receiving bolus feeds, for whom the prandial insulin would be divided equally before each bolus feed. Correction insulin should be administered, as needed, with the prandial insulin.",
"   </p>",
"   <p>",
"    A third approach is to use short-acting insulin alone. This approach is supported by the findings of a randomized trial of sliding scale",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    (SSRI) every four to six hours alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    in 50 non-critically ill patients with diabetes receiving enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/22\">",
"     22",
"    </a>",
"    ]. Insulin doses were adjusted daily based upon finger stick blood glucose measurements, and NPH insulin was added in the SSRI group when glucose levels persistently exceeded 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    There were no differences in any glycemic measures (mean study glucose, mean peak or nadir glucose, hypoglycemia events, or total daily insulin dose) between the two groups. However, NPH insulin was required in 48 percent of subjects randomly assigned to SSRI. Thus, when SSRI alone is chosen as the initial management strategy for patients receiving enteral feeds, the addition of basal insulin is often required to maintain adequate glycemic control.",
"   </p>",
"   <p>",
"    If the enteral feeds (continuous or bolus) are unexpectedly discontinued, an intravenous 10 percent dextrose solution, providing a similar number of carbohydrate calories as was being administered via the enteral feeds, should be infused in order to prevent hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the time, the treatment of hyperglycemia in patients with diabetes in these stressful circumstances can be done by the patient's internist or generalist. However, each clinician needs to decide whether or not the patient would benefit from additional advice; consultation with a diabetes specialist or endocrinologist may help, particularly if accompanied by a team including personnel who can provide patient education and nutritional advice. This team approach can decrease the patient's length of stay as well as decrease the total cost of care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Using the hospitalization to enhance the patient's knowledge about the disease and to improve self-management is encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Evaluation of overall care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief hospitalization is an excellent opportunity to assess or reassess overall care in patients with diabetes. Attention should be paid to preventive measures (such as smoking cessation, control of hypertension, treatment of dyslipidemia, and appropriate vaccinations) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26233/abstract/25\">",
"     25",
"    </a>",
"    ], glycemic control, assessment of possible complications of diabetes, and overall patient education. This should lead to the formulation of a plan for future treatment after the patient is discharged.",
"   </p>",
"   <p>",
"    In type 2 diabetes, an insulin regimen may not be necessary after the illness requiring hospitalization has resolved. In addition, even when such a regimen is considered to be the ideal outpatient therapy upon discharge, the patient may not be able to comply safely with the prescribed insulin program, which requires a degree of education, commitment, and self-discipline not exhibited by all. Thus, it is important to determine both the insulin needs as well as the self-care capacities of each patient prior to discharge. Optimal regimens should be individualized for each patient.",
"   </p>",
"   <p>",
"    Patients may require a significant dose adjustment (usually a lowering of the dose) after discharge from the hospital, which is why clear communication between the clinician dealing with the acute illness and the clinician who will follow the patient's diabetes care after discharge is so important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients found to be newly hyperglycemic during times of illness may actually have undiagnosed diabetes. A glycohemoglobin assay (A1C) can help discriminate between acute, stress-related hyperglycemia and preexistent diabetes. At a minimum, these individuals should be retested as outpatients upon full recovery. Adequate patient education, discharge planning, and the important transition to the outpatient arena are facilitated by nursing personnel dedicated to diabetes care at each institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 1 or type 2 diabetes mellitus are frequently admitted to a hospital, usually for treatment of conditions other than the diabetes. Glycemic control is likely to become unstable in these patients, not only because of the stress of the illness or procedure, but also because of the concomitant changes in dietary intake and physical activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Glycemic goals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correction and prevention of hyperglycemia is beneficial to hospitalized patients. However, the optimal target blood glucose is controversial. For most non-critically ill hospitalized patients with diabetes, we suggest a premeal target of &lt;140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with all random glucoses &lt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Non-critically ill'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In non-critically ill hospitalized patients, there is insufficient evidence to establish a minimal acceptable blood glucose. Lower blood glucose levels may decrease the risk of poor clinical outcomes, but also increase the risk of hypoglycemia. A reasonable glycemic goal to avoid hypoglycemia is to achieve pre-meal blood glucose concentrations no lower than 90 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.0 to 5.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Non-critically ill'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      More stringent goals may be appropriate for stable patients with previous good glycemic control, and the goal should be set somewhat higher for older patients and those with severe comorbidities where the heightened risk of hypoglycemia may outweigh any potential benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of general principles should be kept in mind when managing patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Type 2 diabetes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated by diet alone usually need no specific hypoglycemic therapy. Frequent blood glucose monitoring is warranted to prevent serious hyperglycemia from being unrecognized. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diet treated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with oral antihyperglycemic drugs can continue their usual drug regimen in some circumstances (patient eating, glucose well controlled, and no contraindication to oral agents) (",
"      <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"       algorithm 1",
"      </a>",
"      ). However, if blood glucoses are poorly controlled with the usual oral agents or if the patient is not eating, drug therapy should be discontinued and insulin initiated (",
"      <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patients treated with oral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin therapy should be continued in all patients already taking it to maintain a reasonably constant basal level of circulating insulin (",
"      <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patients treated with insulin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Type 1 diabetes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with type 1 diabetes require insulin at all times, whether or not they are eating. Insulin can be given either subcutaneously or intravenously. For subcutaneous insulin, sliding-scales should never be used as the sole insulin. Optimally, basal insulin (glargine, detemir, or NPH) should be combined with prandial insulin and correction insulin (rapid or short-acting insulin) (",
"      <a class=\"graphic graphic_algorithm graphicRef72627 \" href=\"UTD.htm?25/3/25650\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef59822 \" href=\"UTD.htm?23/51/24369\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients with type 1 diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When intravenous insulin is given, glucose (as dextrose or in TPN or by enteral route) should be administered. Blood glucose should be measured frequently (every one to two hours in patients receiving an insulin infusion). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Insulin infusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/1\">",
"      Ahmann, A. Comprehensive management of the hospitalized patient with diabetes. Endocrinologist 1998; 8:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/2\">",
"      Moss SE, Klein R, Klein BE. Risk factors for hospitalization in people with diabetes. Arch Intern Med 1999; 159:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/3\">",
"      American Diabetes Association. Hospital admission guidelines for diabetes. Diabetes Care 2004; 27 Suppl 1:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/4\">",
"      Hirsch IB, Paauw DS, Brunzell J. Inpatient management of adults with diabetes. Diabetes Care 1995; 18:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/5\">",
"      Turchin A, Matheny ME, Shubina M, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009; 32:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/6\">",
"      Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. Anesth Analg 1999; 89:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/7\">",
"      Nasraway SA Jr. Sitting on the horns of a dilemma: avoiding severe hypoglycemia while practicing tight glycemic control. Crit Care Med 2007; 35:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/8\">",
"      Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/9\">",
"      Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/10\">",
"      Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 1998; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/11\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/12\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/13\">",
"      Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55:3151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/14\">",
"      Jacober SJ, Sowers JR. An update on perioperative management of diabetes. Arch Intern Med 1999; 159:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/15\">",
"      Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/16\">",
"      Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997; 157:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/17\">",
"      Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/18\">",
"      Umpierrez GE, Hor T, Smiley D, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/19\">",
"      Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/20\">",
"      Schoeffler JM, Rice DA, Gresham DG. 70/30 insulin algorithm versus sliding scale insulin. Ann Pharmacother 2005; 39:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/21\">",
"      Wesorick D, O'Malley C, Rushakoff R, et al. Management of diabetes and hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient. J Hosp Med 2008; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/22\">",
"      Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care 2009; 32:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/23\">",
"      Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 1995; 99:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/24\">",
"      Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997; 20:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26233/abstract/25\">",
"      Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000; 23:95.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1770 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26233=[""].join("\n");
var outline_f25_39_26233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS IN THE HOSPITAL SETTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Avoidance of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Avoidance of hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glycemic targets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Non-critically ill",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Critically ill",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION AND TREATMENT OF HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Types of insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sliding-scale insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Correction insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Insulin infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients with type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diet treated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Patients treated with oral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Patients treated with insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients with type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients receiving enteral or parenteral feedings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - TPN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Enteral feedings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Evaluation of overall care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Glycemic goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1770|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/3/25650\" title=\"algorithm 1\">",
"      Hyperglycemia treatment for hospitalized patients on normal diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/51/24369\" title=\"algorithm 2\">",
"      Hyperglycemia treatment for hospitalized patients NPO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28178?source=related_link\">",
"      Illustrative cases of intensive insulin therapy in special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=related_link\">",
"      Susceptibility to infections in persons with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26234="Causes and diagnosis of anemia due to iron deficiency";
var content_f25_39_26234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and diagnosis of anemia due to iron deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26234/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26234/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/39/26234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/39/26234/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/39/26234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of iron deficiency, and the rapidity with which it progresses, is dependent upon the individual's initial iron stores which are, in turn, dependent upon age, sex, rate of growth and the balance between iron absorption and loss. The generally lower value for iron stores in adult women, for example, reflects the composite effect of menstrual losses (approximately 1 mg of iron loss per day), lower caloric intake, use of supplemental iron, and iron losses associated with pregnancy and lactation (about 1000 mg each for pregnancy, delivery, and nursing).",
"   </p>",
"   <p>",
"    Data from the Third National Health and Nutrition Examination Survey (NHANES III; 1988 to 1994) indicated that iron deficiency anemia was present in 1 to 2 percent of adults (",
"    <a class=\"graphic graphic_table graphicRef66255 \" href=\"UTD.htm?13/28/13772\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/1\">",
"     1",
"    </a>",
"    ]. Iron deficiency without anemia was more common, occurring in up to 11 percent of women (most often premenopausal) and 4 percent of men. In this survey, the prevalence of iron deficiency anemia was significantly higher in older adults, being between 12 and 17 percent in persons 65 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=see_link&amp;anchor=H16#H16\">",
"     \"Anemia in the older adult\", section on 'Iron deficiency anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major causes, stages, and diagnosis of iron deficiency in adults will be reviewed here. These issues are best understood if the reader first reviews the regulation of normal iron balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of iron deficiency and issues concerning iron balance in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF IRON DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major cause of iron deficiency in affluent countries is blood loss, either overt or occult [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/4\">",
"     4",
"    </a>",
"    ]. Overt blood loss is, by definition, obvious and not difficult for the clinician to recognize, often by history alone. Examples include severe traumatic hemorrhage, hematemesis, melena, hemoptysis, severe menorrhagia, and gross hematuria.",
"   </p>",
"   <p>",
"    Occult bleeding, on the other hand, may be difficult to track down. This usually occurs via the gastrointestinal tract in men. Other causes are repeated voluntary blood donations, the post-operative setting in which blood loss greatly exceeds the amount of blood transfused, or iatrogenic anemia due to repeated and massive blood drawing in the course of workup of a complicated medical condition. Additional factors are often responsible in women, including underestimating the degree of menometrorrhagia, blood loss during delivery, and direct iron loss to the fetus during pregnancy and to the neonate during lactation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although reduced gastrointestinal absorption of iron (see below) and a diet deficient in iron can also cause iron deficiency, it is most reasonable to believe, as a first assumption, that iron deficiency reflects blood loss, in order to avoiding missing an occult malignancy or other bleeding intestinal lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Search for source of blood and iron loss'",
"    </a>",
"    below.) Two studies lend credibility to this assumption:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 9024 participants in the NHANES I study, men and postmenopausal women with iron deficiency anemia had an increased risk of being diagnosed with a gastrointestinal malignancy within the subsequent two years (relative risk versus non-iron deficient controls 31, 95% CI 9-107) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report dealing with 148 consecutive patients with iron deficiency anemia, 18 patients (12 percent) were found to have a malignant tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/7\">",
"       7",
"      </a>",
"      ]. Using multivariate analysis, the odds ratio for the presence of malignancy in a patient with a serum ferritin &le;10",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      and an LDH &gt;250",
"      <span class=\"nowrap\">",
"       units/L,",
"      </span>",
"      when compared with patients having a ferritin &gt;10 and an LDH &lt;250, was 74 (95% CI 7-776).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decreased iron absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal malabsorption of iron is a relatively uncommon cause of iron deficiency, although it may be observed in certain diseases associated with generalized malabsorption or achlorhydria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the use of proton pump inhibitors, which reduce gastric acid secretion, has not been associated with clinical iron deficiency.",
"   </p>",
"   <p>",
"    Gastrointestinal causes for iron deficiency (eg, atrophic gastritis, Helicobacter pylori gastritis, celiac disease) should be considered in patients with otherwise unexplained iron deficiency, especially when there is refractoriness to oral iron therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Oral iron absorption test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966796\">",
"    <span class=\"h3\">",
"     Foods and medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of foods and medications that impair absorption of iron. These are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'General principles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of patients with iron deficiency anemia, refractoriness to oral iron treatment was noted in all patients with celiac disease and 70 percent of those with autoimmune atrophic gastritis or Helicobacter pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link&amp;anchor=H12#H12\">",
"     \"Metaplastic (chronic) atrophic gastritis\", section on 'Helicobacter pylori'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\", section on 'Iron deficiency anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Celiac disease was the cause of iron deficiency in up to 10 percent of patients referred to a gastroenterologist in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/11\">",
"     11",
"    </a>",
"    ], and in up to 8.5 percent of patients with iron deficiency anemia unresponsive to oral iron therapy in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/12\">",
"     12",
"    </a>",
"    ]. It is unclear whether there is a component of blood loss contributing to iron deficiency in this condition, although a component of the anemia of chronic disease (inflammation) is seen in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Iron deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other uncommon causes of iron deficiency:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular hemolysis, with its accompanying hemoglobinuria and hemosiderinuria can lead to significant urinary iron losses in patients with paroxysmal nocturnal hemoglobinuria and in cardiac patients with intravascular destruction of red cells secondary to malfunctioning valvular prostheses, patches, or intracardiac myxomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Iron'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H18#H18\">",
"     \"Complications of prosthetic heart valves\", section on 'Hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pulmonary hemosiderosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hemosiderosis (eg, chronic pulmonary hemorrhage in anti-glomerular basement membrane antibody disease) can appear as functional iron deficiency. Although the sputum and lung biopsy show large numbers of iron-laden macrophages, the considerable amount of iron present in these macrophages is poorly available for new hemoglobin synthesis, resulting in systemic iron deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link&amp;anchor=H4#H4\">",
"     \"Idiopathic pulmonary hemosiderosis\", section on 'Iron metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Response to erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A response to treatment with erythropoietin (EPO) for the anemia of chronic renal failure often leads to iron deficiency, since the iron requirements generated by this response can usually not be met by mobilization of the patient's iron stores alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/14\">",
"     14",
"    </a>",
"    ]. This is a particular problem in patients on maintenance hemodialysis who lose an average of 2 g of iron per year mainly from repeated blood testing and blood losses within the hemodialysis apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, iron deficiency will develop in all such patients receiving EPO unless supplemental iron therapy is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few calculations illustrate the magnitude of this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The red cell mass in the standard nonanemic 70 kg man is about 2000 mL (25 to 30",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      which contains 2 g of iron.",
"     </li>",
"     <li>",
"      Bringing the red cell mass from one-half normal to normal requires 1 g of iron. When added to the yearly losses of 2 g on hemodialysis, the total iron requirement is 3 g during the first year, an amount equal to three times the normal stores of an average adult man (see below). The result, without iron supplementation, will be negative iron balance and the development of iron deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gastric bypass for morbid obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;This form of surgery bypasses the duodenum, the major site of intestinal iron absorption.",
"   </p>",
"   <p>",
"    As a result, iron deficiency can occur following gastric bypass surgery, not only through the bypassing of the site of major iron absorption, but also as the result of decreased gastric acid availability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H21#H21\">",
"     \"Regulation of iron balance\", section on 'Intestinal iron absorption'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Micronutrient deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Congenital iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare families with iron deficiency anemia unresponsive to oral iron therapy, but partially responsive to parenteral iron, have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of five kindreds, a recessive germline mutation was found in TMPRSS6, which encodes a type II transmembrane serine protease produced in the liver that regulates the expression of hepcidin. Affected individuals had iron deficiency anemia with urinary hepcidin levels that were inappropriately elevated. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Changes in iron metabolism'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H18#H18\">",
"       \"Regulation of iron balance\", section on 'Iron-refractory iron deficiency anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic defects of the iron transporter DMT1 have also been associated with defective iron absorption and utilization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H10#H10\">",
"       \"Regulation of iron balance\", section on 'Duodenal iron transporter'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STAGES OF IRON DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Normal body iron content",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal iron content of the body is 3 to 4 grams. It exists in the following forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin in circulating red cells &mdash; approximately 2 grams",
"     </li>",
"     <li>",
"      Iron containing proteins (eg, myoglobin, cytochromes, catalase) &mdash; 400 mg",
"     </li>",
"     <li>",
"      Plasma iron bound to transferrin &mdash; 3 to 7 mg",
"     </li>",
"     <li>",
"      The remainder is storage iron in the form of ferritin or hemosiderin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Storage iron in adult men has been estimated as being approximately 10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and is found mostly in liver, spleen, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/16\">",
"     16",
"    </a>",
"    ]. Adult women have less storage iron, depending upon the extent of menses, pregnancies, deliveries, lactation, and iron intake. In the study noted above, 93 percent of United States women 20 to 45 years of age had iron stores of 5.5 &plusmn; 3.4",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    while the other 7 percent had an iron deficit of 3.9 &plusmn; 3.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/16\">",
"     16",
"    </a>",
"    ]. Other estimates have suggested that up to 20 percent of menstruating women in the United States have absent iron stores [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For ferritin levels in the range from 20 to 300",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    there appears to be a direct quantitative relationship between the ferritin concentration and iron stores (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Serum or plasma ferritin'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Iron stores (mg) &nbsp;&asymp; &nbsp;(8 to 10) &nbsp;x &nbsp;ferritin",
"    <span class=\"nowrap\">",
"     (ng/mL)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Progressive iron depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of iron deficiency occur in several stages (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/4\">",
"     4",
"    </a>",
"    ]. These stages are defined by the extent of depletion, first of iron stores and then of iron available for hemoglobin synthesis. Eventually, if negative iron balance continues, the iron and hemoglobin deficiency are so severe that iron deficient red cell production ensues.",
"   </p>",
"   <p>",
"    In the first stage, iron stores can be totally depleted without causing anemia. The storage iron pool, consisting primarily of ferritin and hemosiderin-bound iron within the monocyte-macrophage system chiefly in bone marrow, liver and spleen, contains approximately 0.8 to 1.0 g of iron in men and about one-half this value in women (",
"    <a class=\"graphic graphic_table graphicRef76998 \" href=\"UTD.htm?15/22/15723\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Normal body iron content'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The storage pool can be looked upon as a reserve of iron that can be utilized when there is increased need for hemoglobin synthesis, as in acute blood loss, growth in children and adolescents, pregnancy, lactation and response to treatment with erythropoietin. Once these stores are depleted, there is still enough iron present in the body within the \"labile\" iron pool from the daily turnover of red cells for normal hemoglobin synthesis, but the patient is now vulnerable to development of anemia should there be further iron losses (",
"    <a class=\"graphic graphic_figure graphicRef71736 \" href=\"UTD.htm?36/1/36895\">",
"     figure 1",
"    </a>",
"    ). Some subjects with extremely low levels of serum ferritin, but without anemia, may have symptoms of fatigue or show decreased exercise tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H21263646#H21263646\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Treatment of fatigue in nonanemic subjects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23111?source=see_link\">",
"     \"Approach to the adult patient with fatigue\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further loss of iron results in anemia, which is initially normocytic with a normal absolute reticulocyte count (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ). This stage of iron deficiency is common in the United States. As an example, it has been estimated that more than 20 percent of menstruant women in the United States have no iron reserves and are in this stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/19\">",
"     19",
"    </a>",
"    ]. Common laboratory findings at this stage include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low levels of ferritin and serum iron (Fe)",
"     </li>",
"     <li>",
"      Increased levels of transferrin (Tf, total iron binding capacity, TIBC)",
"     </li>",
"     <li>",
"      Low percent saturation of transferrin (ie,",
"      <span class=\"nowrap\">",
"       Fe/TIBC",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       Fe/Tf,",
"      </span>",
"      stated as a percent)",
"     </li>",
"     <li>",
"      Increased unsaturated iron binding capacity (UIBC = TIBC - Fe)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More profound deficiency results in the classical hypochromia (low mean corpuscular hemoglobin) and microcytosis (low mean corpuscular volume) of iron-deficient erythropoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone marrow and EPO responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until recently it was not understood how the balance between availability of iron and heme synthesis on the one hand and globin synthesis on the other hand is achieved. Clinical observations clearly show that iron deficiency, and therefore heme deficiency, results in decreased globin synthesis, hypochromia and microcytosis of circulating red cells, and a mild hypoproliferative anemia.",
"   </p>",
"   <p>",
"    A protein kinase called heme-regulated translational inhibitor (HRI) appears to be the key link in determining the balance between the synthesis of heme and globin. In the presence of",
"    <span class=\"nowrap\">",
"     iron/heme",
"    </span>",
"    deficiency, HRI phosphorylates the alpha subunit of the translational initiation factor eIF2. The eIF2alpha protein kinase then regulates globin synthesis. As an example of this control, induced iron deficiency did not result in the production of hypochromic microcytic anemia in HRI knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentration of erythropoietin is appropriately elevated in iron deficiency anemia, but the absolute reticulocyte count is usually not increased because iron deficiency (specifically a reduction in transferrin-bound plasma iron) becomes rate-limiting for erythropoiesis, thereby impairing the erythropoietic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Changes in iron metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In uncomplicated iron deficiency anemia, both the anemia per se and the absent iron stores provide a message to stop production of hepcidin, a protein produced in the liver which is felt to be a major regulator of iron balance. The absence of hepcidin enhances gastrointestinal iron absorption as well as the release of iron from stores in macrophages. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual presenting symptoms in adults with iron deficiency, as seen in current practice, are primarily due to anemia and include weakness, headache, irritability and varying degrees of fatigue and exercise intolerance. However, many patients are asymptomatic and may recognize that they had fatigue, weakness, exercise intolerance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pica only after successful treatment with iron. The same symptoms may also be present in those with extremely low levels of serum ferritin who are not anemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23111?source=see_link\">",
"     \"Approach to the adult patient with fatigue\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H21263646#H21263646\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Treatment of fatigue in nonanemic subjects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Plummer-Vinson or Patterson-Kelly syndrome (dysphagia, esophageal web, and atrophic glossitis with iron deficiency anemia), koilonychia (spoon nails), chlorosis, and blue sclerae, characteristic of iron deficiency in the early part of the 20th century, have virtually disappeared [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, some patients with iron deficiency (with or without anemia) may complain of glossal pain, reduced salivary flow leading to dry mouth, atrophy of tongue papillae, and occasionally, alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of dysphagia in adults\", section on 'Esophageal webs and rings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Classic presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a \"classic\" presentation of iron-deficiency anemia. The patient, a multigravid woman in her forties, presented with tiredness, fatigue, and chronic blood loss from menometrorrhagia. The following laboratory findings were noted (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin was low at 8",
"      <span class=\"nowrap\">",
"       g/dL;",
"      </span>",
"      mean cell volume (MCV) was low at 75 fL.",
"     </li>",
"     <li>",
"      The mean corpuscular hemoglobin (MCH) was low; a blood smear showed microcytic, hypochromic red cells (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The serum iron was low (10",
"      <span class=\"nowrap\">",
"       mcg/dL)",
"      </span>",
"      and the total iron binding capacity (TIBC, transferrin) was elevated (400",
"      <span class=\"nowrap\">",
"       mcg/dL),",
"      </span>",
"      resulting in a low transferrin saturation of 2.5 percent. The plasma ferritin concentration was markedly reduced (10",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"     <li>",
"      Iron stores were absent in the patient's bone marrow as judged by microscopic examination of the Prussian Blue reaction on a bone marrow aspirate, the \"gold standard\" test for estimating iron stores.",
"     </li>",
"     <li>",
"      Finally, the patient responded briskly to a therapeutic trial of oral iron, with a reticulocytosis, followed by elevations in the hemoglobin concentration and hematocrit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current reality in developed countries is that this classic presentation is UNCOMMON, and that the diagnosis and management of iron deficiency anemia is usually a good deal more complicated. As an example, many, if not most, patients with iron deficiency anemia in the United States have normal red cell indices and a relatively normal peripheral blood smear. In older adults, iron deficiency anemia may have an insidious onset and present with symptoms related to exacerbation of an underlying co-morbidity (eg, increasing angina from coronary artery disease, increased confusion in subjects with dementia, increased dyspnea in those with congestive failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pica and pagophagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pica refers to a perverted appetite for substances not fit as food, such as clay or dirt (geophagia), paper products, or starch (amylophagia). It may be modified by cultural or ethnic factors that affect dietary practices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pagophagia, or pica for ice, is considered quite specific for the iron deficiency state [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. It may be present in patients who are not anemic and responds rapidly to treatment with iron, often before any increase is noted in the hemoglobin concentration. In one study of 55 unselected patients with iron deficiency anemia secondary to gastrointestinal blood loss, pica was present in 32 and pagophagia in 28 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Beeturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional manifestation of iron deficiency is beeturia, in which the ingestion of beets leads to the excretion of red urine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/29\">",
"     29",
"    </a>",
"    ]. This finding is due to increased intestinal absorption and subsequent excretion of the reddish pigment betalaine (betanin) present in beets. Betalaine, a redox indicator, is decolorized by ferric ions, which presumably explains the predisposition to beeturia when adequate amounts of iron are not available for decolorization of this pigment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Restless legs syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency is one of the more common causes of restless legs syndrome (RLS), which has been described as a marked discomfort in the legs that occurs only at rest and is immediately relieved by movement. As an example, in a detailed study of 251 patients with iron deficiency anemia referred for anemia to a community-based hematology practice, the prevalence of clinically significant RLS was 24 percent, approximately nine times higher than that seen in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While overall findings linking RLS to iron deficiency are not conclusive, they warrant the measurement of serum ferritin levels in patients with RLS and a trial of oral iron therapy when ferritin levels are low. Oral iron therapy may also be considered when ferritin levels are within normal range, as some patients with RLS but without iron deficiency may still respond. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H5#H5\">",
"     \"Restless legs syndrome\", section on 'Secondary RLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ESTIMATION OF IRON STORES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's history, complete blood count, red blood cell indices, and examination of the peripheral blood smear usually allow the clinician to make a presumptive diagnosis of iron deficiency anemia. This can be followed by a therapeutic trial of iron administration to provide both confirmation of the diagnosis and therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Therapeutic trial of iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of iron deficiency anemia is made if there is a positive response to a trial of oral iron therapy, characterized by a modest reticulocytosis beginning in about five to seven days, followed by an increase in hemoglobin at a rate of about 2 to 4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    every three weeks until the hemoglobin concentration returns to normal.",
"   </p>",
"   <p>",
"    The limitation of this approach occurs if there is no response, or the response is modest or incomplete. In this setting, the clinician cannot differentiate among poor patient compliance, inability to absorb the iron preparation, an incorrect diagnosis, continued bleeding, or a coexisting condition such as the anemia of chronic disease or renal failure that blocks the full reticulocyte response (",
"    <a class=\"graphic graphic_table graphicRef56310 \" href=\"UTD.htm?21/33/22044\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Failure to respond to oral iron therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Oral iron absorption test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For these reasons, laboratory tests (eg, iron studies, iron panel) are often ordered to confirm the diagnosis prior to initiation of therapy (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ). We find it cost effective to simultaneously order serum iron (SI), total iron binding capacity (transferrin, TIBC), and ferritin. The diagnosis can usually be made from these tests alone without scheduling another visit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/31-35\">",
"     31-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Oral iron absorption test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some conditions (eg, sprue, atrophic gastritis, H pylori infection, gastrectomy and gastric bypass procedures) dietary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medicinal iron may not be adequately absorbed. An oral iron tolerance test has been proposed for detecting such patients, in which a fasting serum iron level is compared to a second serum iron level obtained one to four hours following oral ingestion of one 325 mg tablet of iron sulfate (iron content 65 mg) along with water. An increase in serum iron of at least 100",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    indicates that oral iron absorption is generally adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Serum or plasma ferritin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum or plasma ferritin concentration is an excellent indicator of iron stores in otherwise healthy adults and has replaced assessment of bone marrow iron stores as the gold standard for the diagnosis of iron deficiency in most patients (",
"    <a class=\"graphic graphic_figure graphicRef66419 \" href=\"UTD.htm?13/52/14159\">",
"     figure 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H30\">",
"     'Bone marrow iron'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/33-35,38\">",
"     33-35,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ferritin concentration ranges from 40 to 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (mcg/L)",
"    </span>",
"    in normal subjects, and is markedly elevated in states of iron overload, due to stimulation of hepatic ferritin synthesis and release by iron [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/39\">",
"     39",
"    </a>",
"    ]. There is no clinical situation other than iron deficiency in which extremely low values of serum ferritin are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/34,38\">",
"     34,38",
"    </a>",
"    ]. Thus, virtually all patients with serum ferritin concentrations less than 10 to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are iron deficient, with a sensitivity of 59 percent and a specificity of 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, given the low sensitivity of a ferritin level &lt;15",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    coupled with the fact that, in one study, 25 percent of women with absent stainable bone marrow iron had serum ferritin levels &gt;15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/41\">",
"     41",
"    </a>",
"    ], a higher ferritin cutoff level for suspecting iron deficiency is more appropriate. Provided that an anemic patient does not have an accompanying infectious or inflammatory disease, a cutoff limit of 30 or 41",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for serum ferritin provides improved diagnostic efficiency, with a sensitivity and specificity of 92 and 98 percent, or 98 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum ferritin is useful in diagnosing iron deficiency in pregnant women, who often have an elevated serum transferrin in the absence of iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/32\">",
"     32",
"    </a>",
"    ]. In one study of pregnant women, a serum ferritin concentration &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was the best single indicator of reduced storage iron [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/44\">",
"     44",
"    </a>",
"    ]. When used as a screening test for iron deficiency, it had a sensitivity of 90 percent and specificity of 85 percent. Measurement of serum iron and percent saturation of TIBC had significantly lower diagnostic accuracy. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Serum iron and transferrin (TIBC)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Inflammatory states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferritin is an acute phase reactant, with plasma levels increasing in liver disease, infection, inflammation, and malignancy. As an example, the synthesis and release of ferritin by hepatic cells is directly enhanced by inflammatory cytokines such as interleukin-1 and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, a patient with iron deficiency and a concomitant inflammatory disease such as rheumatoid arthritis may have a \"falsely\" normal ferritin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of inflammation is to elevate serum ferritin approximately threefold [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/18\">",
"     18",
"    </a>",
"    ]. A useful rule-of-thumb in such patients is to divide the patient's serum ferritin concentration by three; a resulting value of 20 or less (ie, an initial serum ferritin &lt;60",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    suggests concomitant iron deficiency. As an example, in a study of anemic patients with rheumatoid arthritis, a serum ferritin concentration &lt;60",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had 83 percent accuracy for predicting a response to oral iron therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although high plasma transferrin and low mean cell volume showed similar predictive values, more patients with iron deficiency anemia could be diagnosed by serum ferritin measurements than by other conventional blood tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H4#H4\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Iron deficiency anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Serum iron and transferrin (TIBC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In iron deficiency anemia, the serum iron concentration (SI) is reduced, and the level of transferrin (also measured as total iron binding capacity [TIBC]) is elevated; the latter finding reflects the reciprocal relationship between serum iron and transferrin gene expression in most nonerythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/46\">",
"     46",
"    </a>",
"    ]. The low SI and high",
"    <span class=\"nowrap\">",
"     transferrin/TIBC",
"    </span>",
"    result in a low transferrin saturation or index (saturation =",
"    <span class=\"nowrap\">",
"     SI/TIBC",
"    </span>",
"    x 100), often to levels less than 10 percent, compared with the normal values of 25 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/18,47\">",
"     18,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H3#H3\">",
"     \"Regulation of iron balance\", section on 'Transferrin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accuracy of measurement of",
"    <span class=\"nowrap\">",
"     transferrin/TIBC",
"    </span>",
"    for predicting the presence of iron deficiency is second only to the serum or plasma ferritin concentration. One problem is that pregnancy and oral contraceptives increase the plasma transferrin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/32\">",
"     32",
"    </a>",
"    ]; as a result, the percent saturation may be low in such patients in the absence of iron deficiency. In one series, a transferrin saturation less than 15 percent was 80 percent sensitive as an indicator of iron deficiency, but only 50 to 65 percent specific [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/48\">",
"     48",
"    </a>",
"    ], yielding a discriminatory index that was inferior to the transferrin concentration alone or to serum ferritin.",
"   </p>",
"   <p>",
"    A low SI is less specific, also occurring in the anemia of chronic disease (anemia of chronic inflammation,",
"    <span class=\"nowrap\">",
"     ACD/ACI);",
"    </span>",
"    in this setting, however, there is usually a parallel reduction in the TIBC, resulting in a near normal percent saturation. However, about 20 percent of patients with",
"    <span class=\"nowrap\">",
"     ACD/ACI",
"    </span>",
"    have transferrin saturations in the iron deficiency range because of an inability to access their normal or even increased marrow iron stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bone marrow iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron in bone marrow macrophages and erythroid precursors (sideroblasts) can be detected with the Prussian Blue stain on marrow spicules. Lack of stainable iron in erythroid precursors as well as marrow macrophages is considered by most clinicians to be the \"gold standard\" for the diagnosis of iron deficiency. In contrast, in uncomplicated anemia of chronic disease, iron is present in marrow macrophages but absent or reduced in erythroid precursors (",
"    <a class=\"graphic graphic_picture graphicRef70226 \" href=\"UTD.htm?6/57/7064\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, bone marrow sampling and testing for stainable iron is expensive, invasive, and usually unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/33\">",
"     33",
"    </a>",
"    ]. It has been replaced in practice by measurement of serum ferritin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Serum transferrin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating transferrin receptor (sTfR) is derived from bone marrow erythroid precursors. It provides a quantitative measure of total erythropoietic activity, since its concentration in serum is directly proportional to erythropoietic rate and inversely proportional to tissue iron availability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, iron deficient patients generally have increased levels of sTfR.",
"   </p>",
"   <p>",
"    While this is generally true, serum ferritin is superior to sTfR for the detection of iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/44,49-51\">",
"     44,49-51",
"    </a>",
"    ]. In one series, for example, 65 apparently healthy nonanemic adults were evaluated for the presence of occult iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/49\">",
"     49",
"    </a>",
"    ]. Fourteen subjects had a serum ferritin &lt;12",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a level which is 100 percent specific for iron deficiency; sTfR was increased in nine and normal in five of these patients, for a false negative rate of 36 percent in this small group. The utility of sTfR is even lower when assessing iron status in patients with the anemia of chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/52\">",
"     52",
"    </a>",
"    ], where it is about as accurate as determination of total iron binding capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levels of sTfR are also elevated in patients with increased erythropoietic rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/46\">",
"     46",
"    </a>",
"    ]. In a study of 30 patients with congenital anemia, ineffective erythropoiesis, and iron overload, serum erythropoietin, ferritin, and sTfR levels were increased to 26, 13, and 7 times control values, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore, an elevated serum sTfR concentration is not specific for iron deficiency as is, for example, a low concentration of serum ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     TfR-ferritin index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the ratio of sTfR (expressed as",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    to ferritin (expressed as",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    or the ratio of sTfR to the logarithm (to the base 10) of the ferritin concentration, may overcome some, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/55\">",
"     55",
"    </a>",
"    ], of the above-noted limitations of measurement of sTfR, and may be especially useful for estimating total body storage of iron in epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/16,51\">",
"     16,51",
"    </a>",
"    ] and for distinguishing between iron deficiency anemia (IDA) and the anemia of chronic disease (ACD, anemia of chronic inflammation) (",
"    <a class=\"graphic graphic_figure graphicRef79053 \" href=\"UTD.htm?15/36/15950\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/43,56\">",
"     43,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This ratio presumably is effective in making this distinction since the numerator (sTfR) is increased in IDA and normal in ACD, while the denominator (ferritin or log ferritin) is decreased in IDA and normal to increased in ACD. Specifically, a",
"    <span class=\"nowrap\">",
"     sTfR/log",
"    </span>",
"    ferritin ratio (TfR-ferritin index) &lt;1 suggests the diagnosis of the anemia of chronic disease (ACD), while a ratio &gt;2 suggests the presence of iron deficiency anemia (IDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/43,56\">",
"     43,56",
"    </a>",
"    ]. Patients with the combination of IDA and ACD will also have a TfR-ferritin index &gt;2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Assessment of iron sufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum ferritin is often ordered to assess whether the patient is iron sufficient, rather than deficient. Using bone marrow iron stores as a gold standard, a study of 259 anemic patients over the age of 65 concluded that, in populations with a prevalence of iron deficiency of less than 40 percent, values of serum ferritin &gt;100",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    reduce the probability of iron deficiency to under 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, defining iron sufficiency for the purpose of predicting a response in anemic patients with chronic renal insufficiency to treatment with erythropoietin requires a relatively high amount of available iron, usually stated as a serum ferritin &ge;100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and a transferrin saturation &ge;20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar levels of ferritin and transferrin saturation are also considered a requirement for an adequate response to treatment with erythropoietin in anemic cancer patients receiving chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Red cell morphology and indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the classic description of iron deficiency as leading to a hypochromic, microcytic anemia (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ), many iron deficient patients in western countries will have normal red cell morphology. Further, the finding of a hypochromic microcytic anemia is not pathognomonic of iron deficiency (",
"    <a class=\"graphic graphic_table graphicRef53867 \" href=\"UTD.htm?28/27/29116\">",
"     table 6",
"    </a>",
"    ), with thalassemia and, less commonly, the anemia of chronic inflammation being the other common conditions encountered in daily practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H19#H19\">",
"     \"Mean corpuscular volume\", section on 'Causes of microcytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to rule out these disorders before beginning a trial of iron therapy, since many patients with thalassemia or chronic inflammation are already iron overloaded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Reticulocyte indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of automated counting of reticulocytes, several reticulocyte parameters are available to clinicians and pathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/57\">",
"     57",
"    </a>",
"    ]. These include reticulocyte volume, reticulocyte hemoglobin content, and reticulocyte hemoglobin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H14#H14\">",
"     \"Automated hematology instrumentation\", section on 'Automated counting of reticulocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility and limitations of these parameters are only now being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a screening of 210 children, a reticulocyte hemoglobin content &lt;26",
"      <span class=\"nowrap\">",
"       pg/cell",
"      </span>",
"      was a stronger predictor of iron deficiency and iron deficiency anemia than serum iron, transferrin, transferrin saturation, ferritin, or circulating transferrin receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 32 hemodialysis patients treated with erythropoietin, a reticulocyte hemoglobin content &lt;26",
"      <span class=\"nowrap\">",
"       pg/cell",
"      </span>",
"      predicted the presence of iron deficiency with a sensitivity and specificity of 100 and 80 percent, respectively, and was more accurate than serum ferritin, transferrin saturation, and percentage of hypochromic red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Red cell zinc protoporphyrin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The last step in the biosynthesis of heme is the addition of iron to protoporphyrin IX. If iron is unavailable, zinc (Zn) substitutes, forming zinc protoporphyrin, which can be measured (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ). This test measures the lack of iron, not why it is unavailable. Thus, the red cell zinc protoporphyrin level (FEP) will be increased in both iron deficiency and the anemia of chronic inflammation in which iron is present but trapped in macrophages and not \"available\" for heme synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of an increased FEP for iron deficiency in adults are significantly less than that of serum ferritin (",
"    <a class=\"graphic graphic_figure graphicRef66419 \" href=\"UTD.htm?13/52/14159\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell zinc protoporphyrin (FEP) is also elevated in lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/61\">",
"     61",
"    </a>",
"    ]. However, FEP levels are not usually elevated in lead poisoning until lead levels are greater than 30",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    Thus, FEP is not a good screening test for mild lead toxicity. However, it is a useful confirmatory test for lead poisoning if blood lead levels are not immediately available, and it can be helpful in monitoring response to therapeutic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening tests in children and adolescents\", section on 'Lead poisoning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H19#H19\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SEARCH FOR SOURCE OF BLOOD AND IRON LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of anemia due to iron deficiency is established, attempts must be made to identify the cause. Several of the common causes, such as colonic and uterine cancer, have ominous prognoses unless discovered and treated promptly. Celiac disease should be considered in all patients, especially those with a history of iron deficiency anemia unresponsive to oral iron therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/11,12,62\">",
"     11,12,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Celiac disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The search for sources of blood loss starts with the patient's history, which in women is directed to menses (",
"    <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"     table 7",
"    </a>",
"    ), pregnancy, delivery, lactation, and, in both men and women, to sources of overt or occult blood loss. Examples include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of gastric or duodenal ulcer disease, H pylori infection, sprue, esophageal varices",
"     </li>",
"     <li>",
"      Family history of a bleeding disorder (eg, von Willebrand disease, hereditary hemorrhagic telangiectasia)",
"     </li>",
"     <li>",
"      Family history of colonic malignancy (eg, hereditary non-polyposis colon cancer)",
"     </li>",
"     <li>",
"      Multiple blood donations",
"     </li>",
"     <li>",
"      Chronic intravascular hemolysis with hemoglobinuria (eg, paroxysmal nocturnal hemoglobinuria, defective prosthetic heart valve)",
"     </li>",
"     <li>",
"      Marathon running [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standard test for detecting occult gastrointestinal bleeding has been the Hemoccult II card, which has a low sensitivity for detecting colon cancer. Other tests for occult blood include the HemeSelect, FECA, and HemoQuant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of occult gastrointestinal bleeding\", section on 'Testing for occult blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent evaluation is determined by the initial findings. The initial test that is performed (colonoscopy or endoscopic examination of the upper gastrointestinal tract) can be chosen based upon the findings on the history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of occult gastrointestinal bleeding\", section on 'Testing for occult blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report, for example, prospectively evaluated 100 patients with presumed occult fecal blood loss with colonoscopy, esophagogastroduodenoscopy, and, if these tests were negative, radiographic examination of the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/63\">",
"     63",
"    </a>",
"    ]. A source of bleeding was identified in 62 patients (62 percent). A lesion was seen on colonoscopy in 25, endoscopic examination of the upper gastrointestinal tract in 36, and both in one.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peptic ulcer disease (duodenal, gastric, or anastomotic) was the primary abnormality found in the upper gastrointestinal tract.",
"     </li>",
"     <li>",
"      Cancer, detected in 11 patients, was the most common finding on colonoscopy.",
"     </li>",
"     <li>",
"      No abnormalities were seen on radiographic studies of the small bowel in 38 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in another series of 89 consecutive patients with iron deficiency anemia and Hemoccult-positive stools [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/65\">",
"     65",
"    </a>",
"    ]. Thirty-four had esophagitis, gastritis, or a gastric erosion, 13 had colon cancer, and no diagnosis was established in 14 (16 percent). An important additional finding was that eight patients had concurrent upper gastrointestinal disease and colon cancer; most of these patients had no symptoms of colonic disease. Thus, in a patient who might be at risk (by age or other risk factors) for colon cancer, the presence of a proximal lesion should not preclude additional evaluation of the colon by colonoscopy or double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2069968\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF IRON DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum or plasma ferritin has replaced assessment of bone marrow iron stores as the gold standard for the diagnosis of iron deficiency in most patients (",
"    <a class=\"graphic graphic_figure graphicRef66419 \" href=\"UTD.htm?13/52/14159\">",
"     figure 2",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Bone marrow iron'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/33-35,38\">",
"     33-35,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal ferritin concentration ranges from 40 to 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       (mcg/L).",
"      </span>",
"      Virtually all patients with serum ferritin concentrations less than 10 to 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      are iron deficient, with a sensitivity of 59 percent and a specificity of 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Given the low sensitivity of a ferritin level &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for diagnosing iron deficiency, a higher ferritin cutoff level for suspecting iron deficiency is more appropriate. Provided that an anemic patient does not have an accompanying infectious or inflammatory disease, a cutoff limit of 41",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for serum ferritin provides improved diagnostic efficiency, with a sensitivity and specificity of 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Once the diagnosis of iron deficiency is established, attempts must be made to identify the cause. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of iron deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Search for source of blood and iron loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of iron deficiency depends upon the clinical presentation and on the complete blood count, blood smear and other laboratory tests. As an example, the differential is extensive when the anemia is mild and red cell indices are normal. The anemia of chronic inflammation is the most common alternative diagnosis, but other considerations in this setting include the anemia of renal failure and endocrine disorders such as hyperthyroidism and hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=see_link\">",
"     \"Anemias due to decreased red cell production\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential in patients with hypochromia and microcytosis includes thalassemia, anemia of chronic inflammation, and the sideroblastic anemias (",
"    <a class=\"graphic graphic_table graphicRef53867 \" href=\"UTD.htm?28/27/29116\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between iron deficiency and the thalassemias is based upon the following. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The family history may be positive for thalassemia",
"     </li>",
"     <li>",
"      Iron stores are absent and serum ferritin levels are low in iron deficiency. Both are normal to increased in the thalassemias.",
"     </li>",
"     <li>",
"      The hemoglobin A2 level is increased in the beta thalassemias, and is often decreased in patients with iron deficiency",
"     </li>",
"     <li>",
"      Red cell production is decreased in profound iron deficiency but relatively well maintained (or increased) in thalassemia. Thus, the red cell count is proportionately low in iron deficiency but disproportionately high in the thalassemias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a patient with iron deficiency anemia, a hemoglobin concentration of 9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and a hematocrit of 28 percent will generally have a red cell count of approximately 3 million, due to decreased production of microcytic hypochromic red cells. In contrast, a patient with beta thalassemia intermedia and a similar hemoglobin and hematocrit may have a red cell count of 4.5 million, due to the production of a normal or even increased number of microcytic and hypochromic cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H19#H19\">",
"     \"Mean corpuscular volume\", section on 'Causes of microcytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Sideroblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sideroblastic anemias may also present with hypochromia and microcytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The diagnosis is established by the demonstration of ringed sideroblasts on Prussian Blue stain of the bone marrow (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/66\">",
"     66",
"    </a>",
"    ]. The more common acquired forms are either drug induced, in which case the agent should be stopped if possible, or due to a myelodysplastic syndrome (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Anemia of chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinction between iron deficiency anemia and the anemia of chronic inflammation (anemia of chronic disease,",
"    <span class=\"nowrap\">",
"     ACD/ACI)",
"    </span>",
"    may be difficult because, as noted above, the iron, TIBC, transferrin saturation, ferritin, and red cell zinc protoporphyrin may fail to distinguish between these two disorders (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, in a typical case of",
"    <span class=\"nowrap\">",
"     ACD/ACI,",
"    </span>",
"    both the SI and TIBC will be low, with a normal or increased level of serum ferritin. In contrast, the TIBC is usually high and the ferritin low in iron deficiency anemia. Measurement of the TfR-ferritin index may further help to separate the two disorders (see",
"    <a class=\"local\" href=\"#H32\">",
"     'TfR-ferritin index'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Evaluation of the clinical setting is critical, particularly looking for a chronic disease that might cause anemia, especially infection, inflammation, or malignancy. Measurement of other acute phase reactants, including the erythrocyte sedimentation rate, plasma fibrinogen, and C-reactive protein, may be helpful in suggesting the presence of an underlying infectious or inflammatory disease. Bone marrow examination can establish the presence or absence of iron in marrow macrophages and RBC precursors (",
"    <a class=\"graphic graphic_picture graphicRef70226 \" href=\"UTD.htm?6/57/7064\">",
"     picture 2",
"    </a>",
"    ), and a carefully designed therapeutic trial may also resolve the issue, with the caveats as noted above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While not clinically available at the present time, measurement of the iron regulatory protein hepcidin may provide useful, if not definitive, information regarding the presence of inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) has developed new guidelines for preventing and controlling iron deficiency based upon age and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?25/39/26234/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For girls ages 12 to 18 and nonpregnant women of childbearing age, the CDC recommends screening for anemia every 5 to 10 years during a routine examination, with annual screens for women with risk factors for iron deficiency. A positive test should be repeated; confirmation of the presence of anemia warrants a trial of oral iron. This recommendation diverges slightly from our suggestion that other studies should be ordered to confirm the CAUSE of iron deficiency prior to beginning iron therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"       \"Iron requirements and iron deficiency in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women should begin taking low dose (30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      oral iron at the first prenatal visit as primary prevention of iron deficiency. Women should also be screened for iron deficiency at the first prenatal visit; the presence of anemia warrants treatment with 60 to 120 mg of iron per day. Iron is best absorbed from an empty stomach in the reduced or ferrous form. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"       \"Treatment of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with a hemoglobin and hematocrit less than 9.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and 27.0 percent, respectively, should be referred to a specialist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H16#H16\">",
"       \"Nutrition in pregnancy\", section on 'Iron'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and postmenopausal women do not need routine screening for iron deficiency. Detection of iron deficiency anemia in these groups warrants a complete evaluation for the source(s) of blood loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15676390\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency should be suspected in patients with hypochromic, microcytic anemia. Suggested tests include, in addition to the complete blood count, red blood cell indices, and examination of the peripheral blood smear: (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Estimation of iron stores'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum iron and total iron binding capacity (transferrin)",
"     </li>",
"     <li>",
"      Serum ferritin",
"     </li>",
"     <li>",
"      Stool specimens for presence of occult blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with iron deficiency have a low serum iron, an increased total iron binding capacity (transferrin), and reduced transferrin saturation. The test with the highest sensitivity and specificity is serum ferritin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A serum ferritin concentration less than 10 to 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      has a sensitivity of 59 percent and a specificity of 99 percent for diagnosing iron deficiency.",
"     </li>",
"     <li>",
"      Given the low sensitivity of a ferritin level &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      a higher cutoff level for suspecting iron deficiency is more appropriate. Provided that an anemic patient does not have an accompanying infectious or inflammatory disease, a cutoff ferritin level of &le;41",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      provides the best efficiency for diagnosing iron deficiency, with a sensitivity and specificity of 98 percent (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Serum or plasma ferritin'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     The differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important disorders to be differentiated from iron deficiency are the anemia of chronic inflammation (anemia of chronic disease, ACD) and thalassemia. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a typical case of ACD, both the serum iron and total iron binding capacity will be low, with a normal or increased level of serum ferritin. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Anemia of chronic inflammation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H7#H7\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Laboratory findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with thalassemia may have a positive family history of anemia, splenomegaly, the presence of target cells and tear-drop shaped red cells on the peripheral blood smear, normal to increased serum iron and ferritin levels, and a normal to increased red blood cell count. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Thalassemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Search for blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency, with or without anemia, is a common condition, most often associated with blood loss, either obvious or occult. Accordingly, every effort should be made to determine whether blood loss is present, as well as its cause. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Blood loss'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Less common causes of iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common causes of iron deficiency include the following. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Other causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravascular hemolysis with iron losses through the urine",
"     </li>",
"     <li>",
"      Gastrointestinal iron malabsorption (often with concomitant gastrointestinal bleeding)",
"     </li>",
"     <li>",
"      Response to therapy with erythropoietin, in which there is a high demand for iron to allow for increased red cell production",
"     </li>",
"     <li>",
"      Pulmonary hemosiderosis",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/1\">",
"      Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/2\">",
"      Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/3\">",
"      Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 2011; 46:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/4\">",
"      Cook JD, Skikne BS. Iron deficiency: definition and diagnosis. J Intern Med 1989; 226:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/5\">",
"      Annibale B, Capurso G, Chistolini A, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med 2001; 111:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/6\">",
"      Ioannou GN, Rockey DC, Bryson CL, Weiss NS. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med 2002; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/7\">",
"      Ho CH, Chau WK, Hsu HC, et al. Predictive risk factors and prevalence of malignancy in patients with iron deficiency anemia in Taiwan. Am J Hematol 2005; 78:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/8\">",
"      Hershko C, Hoffbrand AV, Keret D, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005; 90:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/9\">",
"      Unsworth DJ, Lock RJ, Harvey RF. Improving the diagnosis of coeliac disease in anaemic women. Br J Haematol 2000; 111:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/10\">",
"      Hershko C, Lahad A, Kereth D. Gastropathic sideropenia. Best Pract Res Clin Haematol 2005; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/11\">",
"      Unsworth DJ, Lock FJ, Harvey RF. Iron-deficiency anaemia in premenopausal women. Lancet 1999; 353:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/12\">",
"      Corazza GR, Valentini RA, Andreani ML, et al. Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. Scand J Gastroenterol 1995; 30:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/13\">",
"      Harper JW, Holleran SF, Ramakrishnan R, et al. Anemia in celiac disease is multifactorial in etiology. Am J Hematol 2007; 82:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/14\">",
"      Kalantar-Zadeh K, H&ouml;ffken B, W&uuml;nsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/15\">",
"      Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/16\">",
"      Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood 2003; 101:3359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/17\">",
"      Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/18\">",
"      Cook JD. Clinical evaluation of iron deficiency. Semin Hematol 1982; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/19\">",
"      Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood 1986; 68:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/20\">",
"      Han AP, Yu C, Lu L, et al. Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J 2001; 20:6909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/21\">",
"      HOWELL JT, MONTO RW. Syndrome of anemia, dysphagia and glossitis (Plummer Vinson syndrome). N Engl J Med 1953; 249:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/22\">",
"      Crosby WH. Whatever became of chlorosis? JAMA 1987; 257:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/23\">",
"      Osaki T, Ueta E, Arisawa K, et al. The pathophysiology of glossal pain in patients with iron deficiency and anemia. Am J Med Sci 1999; 318:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/24\">",
"      Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/25\">",
"      Simpson E, Mull JD, Longley E, East J. Pica during pregnancy in low-income women born in Mexico. West J Med 2000; 173:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/26\">",
"      Kettaneh A, Eclache V, Fain O, et al. Pica and food craving in patients with iron-deficiency anemia: a case-control study in France. Am J Med 2005; 118:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/27\">",
"      Reynolds RD, Binder HJ, Miller MB, et al. Pagophagia and iron deficiency anemia. Ann Intern Med 1968; 69:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/28\">",
"      Rector WG Jr. Pica: its frequency and significance in patients with iron-deficiency anemia due to chronic gastrointestinal blood loss. J Gen Intern Med 1989; 4:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/29\">",
"      Tunnessen WW, Smith C, Oski FA. Beeturia. A sign of iron deficiency. Am J Dis Child 1969; 117:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/30\">",
"      Allen RP, Auerbach S, Bahrain H, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol 2013; 88:261.",
"     </a>",
"    </li>",
"    <li>",
"     Brittenham GM. Disorders of iron metabolism: Iron deficiency and overload. In: Hematology Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995.",
"    </li>",
"    <li>",
"     Bridges KR, Seligman PA. Disorders of iron metabolism. In: Blood: Principles &amp; Practice of Hematology, Handin RI, Lux SE, Stossel TP (Eds), 1995. p.ch.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/33\">",
"      Fairbanks VF. Laboratory testing for iron status. Hosp Pract 1990; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/34\">",
"      Zanella A, Gridelli L, Berzuini A, et al. Sensitivity and predictive value of serum ferritin and free erythrocyte protoporphyrin for iron deficiency. J Lab Clin Med 1989; 113:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/35\">",
"      McMahon LF Jr, Ryan MJ, Larson D, Fisher RL. Occult gastrointestinal blood loss in marathon runners. Ann Intern Med 1984; 100:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/36\">",
"      Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/37\">",
"      Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008; 121:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/38\">",
"      Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986; 145:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/39\">",
"      Tran TN, Eubanks SK, Schaffer KJ, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997; 90:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/40\">",
"      Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med 1992; 7:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/41\">",
"      Hallberg L, Bengtsson C, Lapidus L, et al. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol 1993; 85:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/42\">",
"      Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/43\">",
"      Punnonen K, Irjala K, Rajam&auml;ki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/44\">",
"      van den Broek NR, Letsky EA, White SA, Shenkin A. Iron status in pregnant women: which measurements are valid? Br J Haematol 1998; 103:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/45\">",
"      Hansen TM, Hansen NE. Serum ferritin as indicator of iron responsive anaemia in patients with rheumatoid arthritis. Ann Rheum Dis 1986; 45:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/46\">",
"      Lok CN, Loh TT. Regulation of transferrin function and expression: review and update. Biol Signals Recept 1998; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/47\">",
"      Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/48\">",
"      Guyatt GH, Patterson C, Ali M, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 1990; 88:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/49\">",
"      Suominen P, Punnonen K, Rajam&auml;ki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998; 92:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/50\">",
"      Malope BI, MacPhail AP, Alberts M, Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol 2001; 115:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/51\">",
"      Radtke H, Meyer T, Kalus U, et al. Rapid identification of iron deficiency in blood donors with red cell indexes provided by Advia 120. Transfusion 2005; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/52\">",
"      Junc&agrave; J, Fern&aacute;ndez-Avil&eacute;s F, Oriol A, et al. The usefulness of the serum transferrin receptor in detecting iron deficiency in the anemia of chronic disorders. Haematologica 1998; 83:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/53\">",
"      Wians FH Jr, Urban JE, Keffer JH, Kroft SH. Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol 2001; 115:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/54\">",
"      Cazzola M, Beguin Y, Bergamaschi G, et al. Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. Br J Haematol 1999; 106:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/55\">",
"      Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003; 49:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/56\">",
"      Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/57\">",
"      Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/58\">",
"      Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2008; 83:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/59\">",
"      Brugnara C, Zurakowski D, DiCanzio J, et al. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999; 281:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/60\">",
"      Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/61\">",
"      Froom P, Kristal-Boneh E, Benbassat J, et al. Predictive value of determinations of zinc protoporphyrin for increased blood lead concentrations. Clin Chem 1998; 44:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/62\">",
"      Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/63\">",
"      Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med 1993; 329:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/64\">",
"      Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/65\">",
"      Till SH, Grundman MJ. Prevalence of concomitant disease in patients with iron deficiency anaemia. BMJ 1997; 314:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/66\">",
"      Bottomley SA. Sideroblastic anemia. Hosp Pract 1990; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     Wiley JS. Sideroblastic anemias. In: Hematology Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/39/26234/abstract/68\">",
"      Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47(RR-3):1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7150 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26234=[""].join("\n");
var outline_f25_39_26234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decreased iron absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1966796\">",
"      - Foods and medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Response to erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gastric bypass for morbid obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Congenital iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STAGES OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Normal body iron content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Progressive iron depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone marrow and EPO responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Changes in iron metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Classic presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pica and pagophagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Beeturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ESTIMATION OF IRON STORES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Therapeutic trial of iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Oral iron absorption test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Serum or plasma ferritin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Inflammatory states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Serum iron and transferrin (TIBC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bone marrow iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Serum transferrin receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - TfR-ferritin index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Assessment of iron sufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Red cell morphology and indices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Reticulocyte indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Red cell zinc protoporphyrin level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SEARCH FOR SOURCE OF BLOOD AND IRON LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2069968\">",
"      DIAGNOSIS OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Anemia of chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15676390\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      The differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Search for blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Less common causes of iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7150|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/1/36895\" title=\"figure 1\">",
"      Overview of iron homeostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/52/14159\" title=\"figure 2\">",
"      Iron deficiency testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/36/15950\" title=\"figure 3\">",
"      TfR ferritin index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7150|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/57/7064\" title=\"picture 2\">",
"      Anemia chron dis marrow iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 3\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/28/13772\" title=\"table 1\">",
"      Rate iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 2\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/58/33708\" title=\"table 3\">",
"      Lab tests in iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/22/15723\" title=\"table 4\">",
"      Storage iron pool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/33/22044\" title=\"table 5\">",
"      Failure to respond to iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/27/29116\" title=\"table 6\">",
"      Causes of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 7\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9276\" title=\"table 8\">",
"      Causes of sideroblastic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=related_link\">",
"      Anemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=related_link\">",
"      Anemias due to decreased red cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23111?source=related_link\">",
"      Approach to the adult patient with fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_39_26235="Causes elevated sweat chloride";
var content_f25_39_26235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions other than cystic fibrosis associated with elevated sweat chloride concentrations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudohypoaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrogenic diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectodermal dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Glycogen storage disease",
"        </p>",
"        <p>",
"         (type I)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucopolysaccharidoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fucosidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mauriac syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial cholestasis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostaglandin E1 administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogammaglobulinemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Welsh MJ, Tsui L-C, Boat T, et al. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, et al (Eds), McGraw-Hill, New York 1995. p.3801.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26235=[""].join("\n");
var outline_f25_39_26235=null;
var title_f25_39_26236="ACC AHA ESC drugs maintain NSR";
var content_f25_39_26236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Maintenance of sinus rhythm in atrial fibrillation (AF)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or",
"general agreement that the following approach is effective for the",
"maintenance of sinus rhythm in patients with AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Treatment of precipitating or reversible causes of AF before initiating therapy with antiarrhythmic drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence",
"or opinion is in favor of the usefulness of the following approaches",
"for the maintenance of sinus rhythm in patients with AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Antiarrhythmic drug therapy to maintain sinus rhythm and prevent tachycardia-induced cardiomyopathy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Infrequent, well tolerated recurrent episodes of recurrent AF is reasonable as a successful outcome of antiarrhythmic drug therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Outpatient initiation of therapy in patients with no associated heart disease when the antiarrhythmic drug is well tolerated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In patients with lone AF and no structural heart disease, outpatient initiation of propafenone or flecainide therapy in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sotalol in outpatients in sinus rhythm who have little or no heart disease, are prone to paroxysmal AF, a baseline uncorrected QT interval less than 460 msec, normal serum electrolytes, and no risk factors for class III drug-related proarrhythmia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Catheter ablation as an alternative to antiarrhythmic drug therapy to prevent recurrent AF in symptomatic patients with little or no left atrial enlargement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that the following approaches are not useful or may",
"be harmful for the maintenance of sinus rhythm in patients with AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Use of a particular antiarrhythmic drug is not recommended in patients with well-defined risk factors for proarrhythmia with that drug.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Antiarrhythmic drug therapy is not recommended in patients with advanced sinus node disease or atrioventricular node dysfunction unless they have a functioning electronic cardiac pacemaker.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26236=[""].join("\n");
var outline_f25_39_26236=null;
var title_f25_39_26237="A practical guide for treating hypochondriasis with CBT";
var content_f25_39_26237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F53858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F53858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A practical guide for treating hypochondriasis with cognitive-behavioral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Principles and tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explore beliefs",
"       </td>",
"       <td>",
"        Ask patients what they believe is causing their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Define goals",
"       </td>",
"       <td>",
"        Define goals, eg, take responsibility for one's health or improved functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral analysis",
"       </td>",
"       <td>",
"        Analyze behavior to determine antecedents, behaviors and consequences (ABC). Ask about thoughts, behaviors, emotions, and situations that precede, accompany, and follow the symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diary",
"       </td>",
"       <td>",
"        The patient should use a diary in a limited manner to record symptoms, rate their severity, describe the situation during which a symptom occurred, describe how they felt at the time, and what they were thinking at the time. These entries are reviewed during treatment sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family",
"       </td>",
"       <td>",
"        The spouse or parents should be invited to attend one or more treatment sessions so that they understand the treatment. Family members should be directed to stop their responses and accommodations to symptoms that are performed out of concern but which ultimately serve to reinforce hypochondriasis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavior first",
"       </td>",
"       <td>",
"        The focus of treatment is changing thoughts and behaviors. It is easier to first change behaviors, especially for patients who are less psychiatrically minded or more resistant to psychiatric explanations of their illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce maladaptive behavior",
"       </td>",
"       <td>",
"        Behavioral change starts with reducing avoidance behavior and other maladaptive responses to symptoms. This can reduce the frequency and intensity of symptoms, reduce disability, and help facilitate cognitive changes. In addition, clinicians and patients need to decide which adaptive behaviors to increase. These should be clearly specified, realistically attainable, and of value to the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incremental change",
"       </td>",
"       <td>",
"        Behavioral change is approached in a gradual way, with graded increases in desired activities. The difference between current behavior and the desired goals is assessed, and then broken down into manageable steps.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practice",
"       </td>",
"       <td>",
"        The clinician should warn the patient that each increase in previously avoided behavior could cause a transient increase in symptoms. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relaxation",
"       </td>",
"       <td>",
"        Teach relaxation techniques to increase the ability to bear with symptoms, reduce stress, and develop pleasant bodily sensations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social skills",
"       </td>",
"       <td>",
"        Provide social skills training.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regulate emotions",
"       </td>",
"       <td>",
"        Teach patients how to regulate their emotions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive change",
"       </td>",
"       <td>",
"        Cognitive change begins with identifying the patient's thoughts and beliefs about bodily sensations and physical symptoms. The clinician then asks the patient to consider alternative explanations and interpretations of symptoms. Patients record their thoughts about symptoms and practice challenging them by producing and recording more benign explanations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychoeducation",
"       </td>",
"       <td>",
"        Provide psychoeducation about hypochondriasis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Realistic health concept",
"       </td>",
"       <td>",
"        Help the patient develop a realistic health concept. Challenge faulty assumptions, such as the idea that one must be in perfect health in order to function, or that any bodily sensation is pathologic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restructure cognitions",
"       </td>",
"       <td>",
"        Aim to restructure cognitions to accept the role of psychiatric factors in hypochondriasis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstrate role of psychiatric factors",
"       </td>",
"       <td>",
"        Conduct exercises to demonstrate the role of psychiatric factors in health. Biofeedback experiments can help patients understand how their somatic preoccupation perpetuates their symptoms and disability. As an example, if the patient focuses on a normal bodily sensation such as the heartbeat, this will reveal an increase in its apparent intensity. The value of distraction as a method of symptom control can then be demonstrated. These experiments provide personal evidence the patient can use in reconsidering&nbsp;a general medical disorder&nbsp;as the explanation of their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Well-being",
"       </td>",
"       <td>",
"        Address problems affecting well-being, such as difficulties in relationships and at work, cognitive misattributions, and emotional state.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Bornschein S, Forstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.",
"       </li>",
"       <li>",
"        Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26237=[""].join("\n");
var outline_f25_39_26237=null;
var title_f25_39_26238="Contents: Renal physiology";
var content_f25_39_26238=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Renal physiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Renal physiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/61/9173\">",
"           Chapter 10A: Acids and bases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23224\">",
"           Chapter 10B: Buffers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1922\">",
"           Chapter 10C: Intracellular pH",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12762\">",
"           Chapter 11A: Renal hydrogen excretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10089\">",
"           Chapter 11B: Regulation of renal hydrogen excretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28852\">",
"           Chapter 11C: Effect of arterial pH on ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/57/10136\">",
"           Chapter 12A: Distribution of potassium between the cells and ECF",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/24/11657\">",
"           Chapter 12B: Renal potassium excretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15766\">",
"           Chapter 13A: Meaning of urine electrolytes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/1/14355\">",
"           Chapter 13B: Meaning of urine osmolality and pH",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38198\">",
"           Chapter 1A: Introduction to renal function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30771\">",
"           Chapter 1B: Units of solute measurement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14518\">",
"           Chapter 2A: Glomerular anatomy and function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/25/13720\">",
"           Chapter 2B: Renin-angiotensin system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36163\">",
"           Chapter 2C: Determinants of GFR",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/46/10985\">",
"           Chapter 2D: Regulation of GFR and renal plasma flow",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/55/21368\">",
"           Chapter 2E: Clinical evaluation of the renal circulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/2/24617\">",
"           Chapter 3A: Cell model for proximal transport",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36905\">",
"           Chapter 3B: Primacy of sodium transport in proximal function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/20/15684\">",
"           Chapter 3C: Secretory pathways in proximal tubule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/49/36630\">",
"           Chapter 4A: Cell model for loop of Henle transport",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29384\">",
"           Chapter 4B: Countercurrent mechanism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13203\">",
"           Chapter 4C: Maintenance of cell volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9378\">",
"           Chapter 4D: Tamm-Horsfall mucoprotein",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/59/32694\">",
"           Chapter 5A: Distal tubule and connecting segment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33352\">",
"           Chapter 5B: Collecting tubules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/33/19988\">",
"           Chapter 6A: Mechanisms of hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/10/16552\">",
"           Chapter 6B: Antidiuretic hormone and water balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2376\">",
"           Chapter 6C: Aldosterone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/27/42422\">",
"           Chapter 6D: Natriuretic peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/966\">",
"           Chapter 6E: Prostaglandins and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2631\">",
"           Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26822\">",
"           Chapter 6G: Calcium and phosphate metabolism in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/60/42947\">",
"           Chapter 6H: Catecholamines and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/23/24945\">",
"           Chapter 6I: Kinins and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10083\">",
"           Chapter 6J: Erythropoietin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3090\">",
"           Chapter 6L: Summary of hormone actions on the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12662\">",
"           Chapter 7A: Exchange of water between the cells and ECF",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/12/40133\">",
"           Chapter 7B: Exchange of water between plasma and interstitial fluid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7893\">",
"           Chapter 8A: Effective circulating volume and the steady state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/3/17461\">",
"           Chapter 8B: Regulation of the effective circulating volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/37/6744\">",
"           Chapter 8C: Regulation of renal Na+ excretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3922\">",
"           Chapter 8D: Volume regulation versus osmoregulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17875\">",
"           Chapter 9A: Water balance and regulation of plasma osmolality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2886\">",
"           Chapter 9B: Renal water excretion and reabsorption",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6E35A7F40D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_39_26238=[""].join("\n");
var outline_f25_39_26238=null;
var title_f25_39_26239="Battery versus coin AP radiograph";
var content_f25_39_26239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Battery versus coin ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlarged radiographic comparison between the camera battery ingestion (left) and the coin ingestion (right) will show the subtle but characteristic differences between the two foreign bodies. The bilaminar structure of the button battery gives it a double-ring or halo appearance on plain radiograph, whereas the appearance of the coin is homogeneous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara Specter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_39_26239=[""].join("\n");
var outline_f25_39_26239=null;
